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ABSTRACT 
Background. Diabetes requires significant disease management, patient-provider 
communication, and interaction between patients, family members, caregivers, and care 
teams. Emerging patient-facing technologies, such as cellular-enabled glucose meters, 
can facilitate additional care support and improve diabetes self-management. This study 
evaluated patient acceptability, feasibility, and efficacy of a diabetes care support 
program facilitated by cellular-enabled glucose meters.  
Methods. A two-phase study approach was taken. Get In Touch – Phase 1 (GIT-1) was a 
1-month pilot involving patients with type 1 and type 2 diabetes. Get In Touch – Phase 2 
(GIT-2) was a 12-month randomized controlled crossover trial involving patients with 
poorly-controlled type 2 diabetes. Results from GIT-1 and preliminary results from GIT-
2 are presented.  
Results. GIT-1 participants with type 1 (n=6) and type 2 (n=10) diabetes reported the 
intervention and cellular-enabled glucose meter were easy to use and useful while 
identifying potential areas of improvement. GIT-2 participants in both the intervention 
(n=60) and control (n=60) groups saw significant improvements in treatment satisfaction 
and A1c change, with intervention participants experiencing slightly greater 
improvements in each after 6 months (p=0.09 and p=0.16, respectively) compared to 
control participants.  
Conclusions.  Patients reported favorable acceptability of the intervention. Preliminary 
results from a randomized trial demonstrated potential of intervention to improve patient-
reported and physiological health outcomes. Future studies should evaluate feasibility 
 
 
 
and efficacy over a longer period of time, with a greater number of participants, and 
targeting different populations of patients with diabetes. Provider perspectives and 
changes in provider behavior, clinical work flow, and caregiver burden should also be 
assessed.  
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 INTRODUCTION 
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Diabetes in the US 
Diabetes is one of the most prevalent and costly chronic diseases in the United 
States. The American Diabetes Association (ADA) estimates that over 22 million 
Americans were diagnosed with either type 1 (T1D) or type 2 (T2D) diabetes in 2012. 
This number increased from an estimated 17.5 million in 2007.[1] If the prevalence of 
diabetes continues to rise at this rate, up to one-third of adults in the US could have 
diabetes by 2050.[2] This is particularly concerning because diabetes is associated with 
many other health complications including being the leading cause of kidney failure, limb 
amputations, and blindness, a major cause of cardiovascular disease and stroke, and the 
seventh leading cause of death in the US.[3] Diabetes is also becoming increasingly 
expensive to treat. The estimated cost of diabetes in the US was $174 billion in 2007 and 
$245 billion in 2012. After accounting for inflation, the 2012 cost estimate is more than 
$43 billion greater than the 2007 estimate.[1] 
Physiology of Diabetes 
In general, diabetes is a group of metabolic diseases that are characterized by 
elevated blood glucose levels.[4] Blood glucose levels are regulated by insulin, a 
hormone produced by the pancreas to convert sugar, starches and other food into energy. 
In T1D, accounting for only 5-10% of the diabetes population, there is an absolute 
deficiency of insulin secretion due to destruction of the β-cells of the pancreas.[4] In 
T2D, accounting for over 90% of diabetes cases, individuals usually experience insulin 
resistance with no or only relative deficiency of insulin secretion.[4]  Resistance of 
insulin by important body tissues, such as the liver, muscle, adipose tissue, and 
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myocardium, results in both glucose overproduction and underutilization.[5] When blood 
glucose levels are elevated, patients experience episodes of hyperglycemia with common 
symptoms including shortness of breath and nausea. Long-term complications of 
hyperglycemia include cardiovascular disease, nerve damage, kidney failure, formation 
of cataracts, and problems with one’s feet, bones and joints. Extended periods of 
hyperglycemia can lead to emergency cases of diabetic ketoacidosis or hyperglycemic 
hyperosmolar syndrome, both of which can lead to diabetes comas and be life 
threatening. Hypoglycemia occurs when blood glucose levels fall and cannot return to 
normal level. Hypoglycemic events can occur due to an excess of exogenous or 
endogenous insulin. Symptoms of hypoglycemia include confusion, irritability, 
lightheadedness, and nausea and if untreated, hypoglycemia can lead to seizure or 
diabetes coma.  
Living with Diabetes 
Management of diabetes is very complex, with an array of pharmacological 
options and lifestyle interventions that should be tailored based on the individual needs, 
preferences, and tolerances of each patient.[5] After a treatment plan is decided, 
executing the plan requires significant effort dedicated to health-related activities. The 
effort spent managing one’s health has been referred to as ‘patient work’.[6] The 
subsequent sections highlight particular instances of patient work that is often required of 
patients with diabetes, as well as their family members and caregivers, to effectively 
manage their diabetes. 
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Self-Monitoring Blood Glucose 
To maintain safe glycemic levels, it is important for patients with diabetes to 
actively monitor their blood glucose throughout the day. The frequency and timing of 
self-monitoring blood glucose (SMBG) testing may vary based upon the needs of each 
individual but it is commonly recommended that patients, especially those with T1D or 
being treated with insulin, test at least 6-8 times per day.[7] Active SMBG testing allows 
patients to detect high or low blood glucose levels, facilitates therapeutic adjustments, 
educates and engages patients in disease self-management, and motivates patients 
towards improving their health.[8] Frequency of testing has been associated with health 
benefits such as improved hemoglobin A1c % (A1c) levels,[9, 10] a key indicator of 
blood glucose control.  
Medication Administration 
Many patients with diabetes take oral medications, inject insulin, or do both to 
help control their blood glucose levels. The Centers for Disease Control and Prevention 
estimates that among all adults with diabetes in 2011, over 80% took either daily oral 
medication or used insulin to manage their diabetes with 50%  only taking oral 
medications, 18% only taking insulin, and 13% taking both oral medications and 
insulin.[11] In addition to daily adherence to prescribed medication regimens, insulin-
using patients may need to adjust their insulin intake at any given point based upon their 
SMBG levels. Injecting an inappropriate amount of insulin can lead to dangerous 
episodes of hypo/hyperglycemia and additional health complications.   
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Behavior Modification and Data Tracking 
Lifestyle changes, specifically those related to one’s diet and physical activity, 
play major roles in the treatment and management of diabetes.[12] Just as obesity and 
sedentary lifestyles are independent predictors to the development of T2D, weight loss 
and increased physical activity have been shown to improve diabetes related health 
outcomes.[5, 13, 14] Tracking how blood glucose levels respond to changes in regular 
activities can inform patients on how best to manage their health. While education upon 
diagnosis is critical and takes advantage of a teachable moment, repeated delivery of 
counseling throughout the management of diabetes is also very important.[5] As patients 
learn more about their disease and the way their body reacts to certain stimuli, self-
management of their health should improve.  
Communication with Care Team 
It is important for patients to communicate with their care team about their 
symptoms and experiences managing their disease. Patient-provider communication has 
been shown to be independently related to diabetes outcomes.[15] Sharing SMBG data 
gives providers valuable information regarding how best to treat their patients. The 
availability of SMBG data can enable care teams to help troubleshoot problems with 
hypo/hyperglycemia and allow them to make alterations to treatment plans accordingly. 
Also, as patients and providers interact more outside of their routine, episodic office 
visits, there are more opportunities for patients to become engaged and active participants 
in their healthcare decisions, which have been shown to be correlated with greater 
treatment satisfaction.[16]   
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Technology Used to Improve Diabetes Management and Ease Patient Work 
Patient Portals 
An electronic patient portal (portal) is an Internet-enabled personal health record 
tethered to a health care provider’s electronic health record system.[17] The functions of 
a portal vary depending on the system with many portals allowing patients to access their 
personal health information (PHI), including lab results, medication information, and 
office notes. Portals can also accommodate secure messaging between patients and 
providers or be used by patients to request medication refills and appointments or for 
provider offices to send appointment and wellness reminders. Particularly relevant to 
patients with diabetes, portals can facilitate a way for patients to electronically collect and 
share data such as symptoms, logbooks (medications, diet, physical activity), or health 
data such as weight, blood pressure, or SMBG levels. Portals can also provide patients 
with access to educational resources aimed to improve patient knowledge and 
management skills.  
The use of portals in the management of diabetes has been shown to improve 
clinical outcomes. In particular, diabetes management programs using patient portals 
have resulted in improved A1c and cholesterol levels.[18-21]  Portal use with secure 
messaging has also been shown to reduce the utilization of clinical services,[22] improve 
disease management and diabetes distress,[23, 24] and is associated with increased 
patient activation[25] and diabetes knowledge.[23] The use of portals also offers an 
additional opportunity for patients and providers to connect outside of their routine face-
to-face appointments. This improvement in the continuity of care delivery has potential to 
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improve clinical outcomes and the patient-provider relationship. Portal users report 
having better communication[26, 27] and improved satisfaction with their providers.[18] 
Portal use has also resulted in an increase in treatment regimen adjustments[28] and 
offers an alternative form of care for patients who are dissatisfied with the regular care 
they receive from their providers.[27] 
Telehealth Coaching 
Delivery of diabetes self-managed education (DSME) has been identified as a 
critical component of diabetes care.[29] Several interventions have used coaches to 
deliver educational and/or disease management training to patients with diabetes. Health 
coaching has been defined as a form of education that guides and prompts a patient to be 
an active participant in behavior change.[30] A recent review found that diabetes health 
coaching resulted in reduction of A1c levels.[31] While the benefit of using health 
coaches for patients with diabetes has been established, there remains potential to 
maximize the benefits. Health coaching sessions have historically been scheduled, in-
person visits. This is good for patients to set long-term goals but may not be as 
convenient or helpful as providing ongoing support or support during the critical 
instances when patients are experiencing symptoms of their health condition. In such 
instances additional support from coaches using increasingly common telehealth 
technologies such as phone calls, instant messaging, or video conferencing, could greatly 
improve the accessibility, convenience, and continuity of care provided, thus increasing 
the benefits generated by health coaches.  
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Computer-Generated Support Messaging 
In addition to human coaches who provide patients with valuable education and 
training to help manage their diabetes, technologies have been developed to deliver 
tailored feedback to patients. Computer programs can factor in various health data to 
generate, select, and deliver short motivational or educational messages that are relevant 
to a patients’ current health status. Computer-generated feedback has resulted in 
improved diabetes outcomes such as lowering A1c, increasing medication adjustments, 
and improving patient and provider satisfaction.[18] While computer-generated support 
has been shown to be helpful, it is still missing the critical component of human-to-
human interaction. If generic, computer-generated messages were augmented with human 
support, it is possible that even greater benefits could be realized.  
Barriers to Technology-Based Interventions 
Despite the potential benefits, the use of technology to manage diabetes is limited 
by several barriers. These barriers vary in type and can prevent patients, caregivers, and 
providers from getting started and/or sustaining use of various technologies.   
Physical/Access Barriers 
In order for patients to use technology to help manage their diabetes, several 
physical and access barriers may need to be addressed. Patients need to own the 
equipment. In most cases of technology-based interventions, this requires access to an 
Internet-enabled device. Patient access to the technology may be limited and not 
continuous. Uploading SMBG data to a portal, for example, has historically required 
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manually connecting a glucose meter with a computer. This restricts the ability to upload 
to occasions where a computer and connectivity are both available.  
Technical Capacity Barriers 
There are also technical capacity barriers that may limit the use of technology to 
manage diabetes. Patients need to know how to properly use the technology, such as how 
to connect a glucose meter to the computer and execute an upload. Even after data are 
uploaded, patients may not know how to interpret or utilize different functions of the 
technology. They also might not be aware of all the functions offered by the technology 
they posses or forget required log-in information.  
Provider-Related Barriers 
There may also be provider-related barriers that limit technology use for diabetes 
management. Providers may not endorse or recommend the use of electronic 
management tools by their patients for different reasons. They could doubt the potential 
benefits, have concerns that use will create uncompensated work for them, or think that 
they will be responsible for more data than they are able to keep up with. Studies have 
shown how influential a provider recommendation can be[32, 33] and that the potential of 
telehealth to help patients with diabetes is dependent on consistent, supportive 
interactions with health care providers.[34] To maximize the use of patient-facing 
technologies to manage their disease, providers need to be on board.  
Addressing Barriers with Cellular-Enabled Glucose Meters 
One technology with potential to address many of the barriers of using 
technology-based innovations is the cellular-enabled glucose meter. Cellular-enabled 
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glucose meters, like the In Touch meter offered by Livongo Health Inc. (Livongo, 
Chicago, IL), have a suite of management tools built into the machine and a touch screen 
interface that is designed to be user friendly. These type of meters utilize built-in cellular 
capability to instantly upload SMBG data to a secure portal, eliminating the physical 
barriers of owning a computer or connecting multiple devices. This allows patients to 
upload their personal health information with greater ease and frequency. Simplifying 
and streamlining the process of testing and uploading SMBG recordings to a secure 
portal could lead to increased frequency of testing and improved self-monitoring, which 
have been correlated with improved health outcomes.[9]  
The use of cellular-enabled glucose meters to automatically upload SMBG 
recordings to a portal can also facilitate the unique opportunity to monitor the data in 
real-time. This allows care team members to provide more responsive and proactive 
support by communicating with patients about what is going on at that very moment. 
Members of the care team can provide self-management support, answer health-related 
questions, or direct patients to resources tailored to their specific needs at that moment. 
While previous studies have looked at sending generated messages in response to 
episodic uploading of SMBG data to a portal,[18] none have looked at in-the-moment, 
person-to-person support facilitated by automatic SMBG uploading by cellular-enabled 
glucose meters.  
While physicians and nurses may not have the capacity, certified diabetes 
educators (CDEs) can be trained to monitor incoming data from patients and provide 
timely support when needed. CDEs are trained to help patients understand their treatment 
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plan and to direct them to reliable educational resources. CDEs can also report to the 
regular care team with valuable information about the health of their patients, helping 
them understand how to improve the care they delivery to their patients. This degree of 
continuous, tailored support is very unique and bridges episodic interactions typically 
seen between patients and their providers. In order to implement the use of cellular-
enabled glucose meters into routine diabetes care, we must first evaluate the 
acceptability, feasibility, and efficacy of interventions utilizing them.  
Specific Aims 
This dissertation used mixed-methods analyses to evaluate the effects of the 
Livongo for Diabetes care support program and the In Touch cellular-enabled glucose 
meter provided by Livongo. The specific aims of this dissertation were as follows:  
Aim 1: Evaluate acceptability of the Livongo for Diabetes care support program and the 
In Touch cellular-enabled glucose meter.  
• As informed by the Technology Acceptance Model (TAM) 
Aim 2: Evaluate feasibility of supplementing usual care with the Livongo for Diabetes 
care support program and the In Touch cellular-enabled glucose meter.  
• As determined by comparison of change in patient-reported diabetes 
treatment satisfaction between intervention and control group participants.  
Aim 3: Evaluate preliminary efficacy of the Livongo for Diabetes care support program 
and the In Touch cellular –enabled glucose meter.  
• As determined by comparison of change in A1c between intervention and 
control group participants.   
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CHAPTER II 
 GET IN TOUCH - PHASE 1:  
EVALUATING ACCEPTABILITY OF A DIABETES CARE SUPPORT 
PROGRAM FACILITATED BY CELLULAR-ENABLED GLUCOSE METERS 
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Abstract 
Background 
Connected health technologies are being used in diabetes care management and 
support programs to facilitate improvements in patient care. Uploading of patient SMBG 
recordings to electronic personal health records provides patients, providers, and 
caregivers with access to longitudinal data.  To improve the utility of this access, SMBG 
data in the glucose meters should be uploaded both consistently and frequently. 
Unfortunately for patients who already deal with high disease management demands 
associated with diabetes, manually uploading SMBG recordings on a regular basis may 
not be practical. New types of personal glucose meters that are cellular-enabled can 
automate the uploading process. These cellular-enabled glucose meters eliminate the 
need for patients to connect to a computer or mobile device to upload SMBG data. 
Automatic uploading of SMBG data to a secure, cloud-based location enables diabetes 
care programs to provide timely and tailored support. As SMBG recordings are 
consistently uploaded to the cloud, computer programs can analyze the data and send 
back tailored feedback to the patient. Certified health professionals can monitor uploads 
in real-time and provide in-the-moment patient support when needed.  
Despite the potential to improve diabetes management, the use of cellular-enabled 
glucose meters to facilitate additional care support is challenging. Although intended to 
be simple and easy to use, new meters can require a degree of technological skill that 
certain patients may not possess. Patients may also struggle to understand how best to 
utilize a meter’s functionality, integrate the technology into existing routines, or use the 
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technology to interact more meaningfully with their care team. For these reasons, patient 
acceptability of care support programs utilizing cellular-enabled glucose meters must be 
evaluated before being implemented more broadly into diabetes care delivery.  
Objective 
To evaluate patient acceptability of a diabetes care support program facilitated by 
cellular-enabled glucose meters.  
Methods 
Patients with type 1 and type 2 diabetes received cellular-enabled glucose meters 
as part of a diabetes care support program in which they were enrolled. CDEs 
continuously monitored uploaded SMBG recordings, provided structured support to 
participants, and interacted with participants’ medical providers as necessary. After 1 
month, focus groups and semi-structured phone interviews were conducted with the 
participants. Audio recordings of each were transcribed verbatim and the resulting 
transcripts were analyzed using a constant comparative method to identify key themes. A 
deductive and inductive, iterative approach was taken by first generating an a priori code 
list based on the TAM, inductively developing additional codes within the TAM 
elements, and revising and refining the code list over several rounds of review.   
Results 
Participants with type 1 (n=6) or type 2 (n=10) diabetes all reported that the 
cellular-enabled glucose meter was easy to use and useful. The most favorable features of 
the meter were the automatic uploading of SMBG recordings, SMBG tracking and 
sharing tools, and tips provided through the meter. The support provided by the CDEs 
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through the care support program was also identified as being helpful. Identified areas of 
improvement included the need for training on the meter and program, improved 
consistency and efficiency of the meter’s functional performance, and additional meter 
functionality. 
Conclusions 
All participants who finished the study reported a positive overall experience 
using the meter as part of the care support program. Future work should focus on long-
term patient acceptability, feasibility and efficacy of using cellular-enabled glucose 
meters in diabetes care support programs and the subsequent effects on clinical service 
utilization and provider workflow. 
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Introduction 
To prevent complications, patients with diabetes must actively manage their 
disease. This includes frequent interactions with their health care team, daily SMBG 
levels, and for many patients, adjustment and administration of insulin therapy, adherence 
to strict oral medication, diet, and physical activity regimens. Recently published 
frameworks[35] based on substantial previous research on the experience and 
management of chronic illness[36, 37]  underscore the importance of understanding the 
kinds of ‘work’ that patients face. The demands and burden of such patient work are 
significant for those with chronic diseases like diabetes. Many patients do not have the 
skills or support to adequately satisfy them. This consequently may result in frustration 
and poorly controlled diabetes.  
SMBG, Diabetes Care Programs and the Future Role of Technology 
The practice of using personal glucose meters to self-monitor blood glucose levels 
among those with diabetes has become increasingly common since the introduction of the 
personal use glucose meter in 1981.[38] Uploading SMBG recordings from personal 
glucose meters into web-based patient portals accessible by patients, caregivers, and care 
teams has potential to improve patient activation, treatment satisfaction, and lower A1c 
levels.[39] Increasing the adoption and sustained use of uploading SMBG recordings 
over time for the general population, however, has its challenges. Identified barriers to 
uploading SMBG recordings include physically connecting the glucose meter to a 
computer or electronic device and having the technological capacity to successfully 
perform this task without assistance.[40] Among those who are able, many may believe 
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that routinely uploading is too burdensome. Automating the uploading process by using 
cellular-enabled glucose meters could have a significant impact on improving the use of 
SMBG recordings for blood glucose monitoring and management.  
While uploading of SMBG recordings can improve patients’ self-management of 
their diabetes, how the uploaded data should be used to improve diabetes care delivery 
still must be determined. Ideally, providers would monitor their patient’s uploaded 
SMBG recordings and provide timely support. The amount of time required to do this, 
however, may not be possible for providers who have many other demands on their time. 
This would be particularly true with the use of cellular-enabled glucose meters that 
automatically upload after each testing. Using other health professionals to monitor 
uploaded recordings and provide appropriate and timely support has potential to improve 
diabetes care while limiting burden on providers. Recent studies have shown benefits of 
utilizing uploaded SMBG data to facilitate care support interventions led by various non-
physician health care professionals including pharmacists,[41] nurses,[42] and care 
managers.[21]  
Diabetes care programs exist to help patients improve their disease 
management.[19] Goals of diabetes management include improving care by facilitating 
communication between patients and their health care team and increasing patient self-
management skills. In some cases, these programs have shown to improve A1c, blood 
pressure, and cholesterol levels.[19, 43-45] Other studies have shown no effect.[46] 
Hospital systems are using emerging technological innovations to assist in diabetes care 
support programs. Two examples of these technologies include advanced glucose meters 
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and web-based personal health records, often referred to as patient portals. Both of these 
technologies can support improved management and sharing of patient-generated data 
and delivery of tailored feedback from health care teams. This improvement in the 
continuity and patient-centeredness of care has potential to improve both clinical 
outcomes and the patient-provider relationship. Patients who use patient portals report 
better communication [26, 27]  and increased satisfaction with their providers.[18] Portal 
use increases treatment regimen adjustment frequency.[28]  
Addressing Challenges to Innovation in Technology Use 
Despite potential benefits, patient adoption and use of new and innovative 
technologies to manage diabetes is not without barriers. A systematic review on the 
barriers of adopting and utilizing patient portals found that in addition to being unaware 
of a portal and its functions, many patients with diabetes cannot access the technology or 
do not possess the technological skills required to use it effectively.[40] This suggests 
additional efforts to both increase access to technologies and to simplify the technological 
processes required may be needed to adequately support certain patients. In the case of 
diabetes management, the use of cellular-enabled glucose meters can potentially help 
address some of the established barriers to technology use.  
Cellular-enabled glucose meters can automate the process of uploading SMBG 
recordings, facilitate improved communication and continuous support from care teams, 
and provide patients with a suite of tools typically accessed through a patient portal. By 
uploading SMBG recordings to a secure portal automatically after a patient tests their 
blood glucose, cellular-enabled glucose meters alleviate the need for patients to manually 
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connect a meter to a computer or wireless device for upload. After the SMBG data is 
uploaded to a secure portal, patients and their designated health care team and caregivers 
can access these recordings in real-time. This allows for improved tracking and the 
potential for provision of timely support. Modern glucose meters are also equipped with 
various tools to assist patients with the self-management of their diabetes. These tools can 
include tailored messages and tips delivered through the meter after testing, personalized 
logbooks, built-in activity trackers, and ways to communicate and share patient-generated 
data with their care team and formal or informal caregivers. Cellular-enabled glucose 
meters also reduce the need for patients to use a computer or mobile device to log onto 
their portal as many of the portal tools are incorporated into the meter’s functionality. 
This could be of great benefit to those who don’t own a computer or don’t have the skills 
to effectively operate one. 
Study Aim 
The aim of this study was to evaluate the acceptability of a diabetes care support 
program facilitated by cellular-enabled glucose meters. We used the TAM to guide this 
evaluation. 
Methods 
We conducted an acceptability study in which we sought to recruit 20 patients 
with either T1D or T2D to enroll for one month in a diabetes care support program 
facilitated by cellular-enabled glucose meters. 
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Sampling and Recruitment 
A convenience sample of twenty-one patients with either type 1 or type 2 diabetes 
was recruited at the UMass Medical Diabetes Center of Excellence (DCOE).  The DCOE 
combines basic science, translational research, and clinical care and serves as an integral 
component of UMass Memorial healthcare network. The DCOE is located in Worcester, 
MA and actively serves over 7,000 adults with diabetes. Research assistants recruited 
patients in the waiting room of the clinic during routine appointments. Participants were 
required to be able to speak English. Eligible patients were shown the In Touch meter and 
described the Livongo for Diabetes care support program. Interested patients signed 
consent forms and provided their contact information. Recruitment took place from 
5/23/14 to 6/6/14. Providers of patients enrolled were notified of their participation.  
Description of Intervention 
Upon providing informed consent, enrolled participants were mailed an In Touch 
cellular-enabled glucose meter to use for 30 days and a one month’s supply of testing 
strips, lances, and lancets. They were also mailed instructions on how to self-enroll in the 
Livongo for Diabetes care support program, an accredited program by the AADE 
Diabetes Education Accreditation Program. The program included both scheduled and in-
the-moment support provided by CDEs certified through the National Certifying Board 
for Diabetes Educators (NCBDE). If participants did not successfully self-enroll after 1 
week from study enrollment, they received a follow-up phone call from study staff to 
assist in the self-enrollment process. All meter equipment and services from the care 
support program were provided by Livongo. The cellular-enabled glucose meter 
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automatically uploaded all glucose recordings to Livongo’s secure patient portal. 
Automated messages including helpful hints designed to assist participants in managing 
their diabetes, such as “Your BG is within range. Learning to eat what is right for your 
body is key to managing your Diabetes”, were sent directly to the meter after each 
testing. These messages were developed using the American Association of Diabetes 
Educators (AADE) National Standards for DSME curriculum.[47] An algorithm 
selectively picked each message based on participant-provided data and the uploaded 
SMBG recordings. Other features of the meter included the ability to tag each recording 
with important contextual information about when it was taken (before meal, after meal, 
neither) and how they were feeling at the time, tracking SMBG recordings with an 
electronic log book, and a built-in activity tracker. The meter also allowed participants to 
share their SMBG data with anyone they designated as part of their care team (including 
their endocrinologist, primary care provider, caregiver, or family member) via text 
message, e-mail, or fax.  
As part of the diabetes care support program, CDEs employed by Livongo 
monitored all SMBG recordings flagged for being dangerously high or low.  The CDEs 
called participants the first time their blood glucose recording was above 250 mg/dL and 
greater than 400 mg/dL thereafter. The CDEs would also call participants if their SMBG 
recordings were below 40 mg/dL at any time during the study period.  If an uploaded 
recording generated an alert for being too high or low, a CDE would contact the 
participant within 3 minutes of receiving the notification. The CDEs also provided 
support through scheduled coaching sessions over the phone and emails, as requested by 
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participants. All coaching sessions were based on the AADE’s 7 self-care behaviors.[48] 
While CDEs did not give participants medical advice or make changes to their care plans, 
they could educate and answer diabetes-specific questions ranging from nutrition to 
lifestyle changes and contacted the participants’ providers if they believed the uploaded 
SMBG recordings or conversations with the participants warranted clinical attention.  
In cases of technical support issues, participants were directed to call Livongo’s 
technical support staff. All SMBG recordings uploaded to Livongo’s portal were sent to 
the DCOE every Friday evening through encrypted email to the study’s Principal 
Investigator, who reviewed and manually added the SMBG recordings to each 
participant’s electronic medical record as a note.  
Framework 
As is the case with any new technology, degree of utilization often determines 
extent of benefits achieved. According to the TAM (Figure 2.1), utilization of a new 
technology is determined by a person’s behavioral intention.[49] This behavioral 
intention, also called acceptability of the technology, is directly influenced by two 
factors; the perceived ease of use and usefulness. Perceived ease of use can also directly 
affect perceived usefulness while both can be affected by other external factors. In the 
context of this intervention, how easy patients believe the meter is to utilize will have an 
effect on how useful they believe it is. If patients don’t believe the meter is both easy to 
use and useful, they most likely will not use it. The same logic can be applied to the 
diabetes care support program. Patients need to believe it is both easy or convenient to 
participants in the program, and also useful, in order for the patients to utilize the services 
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provided. To determine the acceptability of using cellular-enabled glucose meters to 
facilitate diabetes care support programs, it is important to establish how easy to use and 
how useful patients think the technology and program are.  
Data Collection Instruments 
A background questionnaire, focus group guide, and semi-structured interview 
guide were developed by the research team. The focus group and semi-structured 
interview guides were nearly identical and designed to elicit data on concepts related to 
patient acceptability, as described by the TAM. Additionally, the guides included 
questions to identify areas of improvement, evaluate overall experience, determine 
whether they would continue in the care program if covered by their insurance, if they 
were willing to pay out-of-pocket for the services they received, and if yes, how much 
they believed was a reasonable cost. The questionnaire consisted of demographic 
questions. 
Data Collection Procedures 
Participants were invited to come back to the DCOE 1 month after study 
enrollment for a focus group. Participants unable to attend a focus group were called to 
complete a semi-structured interview and the questionnaire over the phone. Three focus 
groups took place between June 24, 2014 and July 9, 2014. Each focus group had 
between 4-5 participants (Group 1: n=4, Group 2: n=4, Group 3: n=5) and were 
facilitated by author DA. One of the DCOE endocrinologists involved in the study also 
attended each focus group to observe and provide medical insight when necessary. Some 
of the study participants in the session were patients of the endocrinologist attending the 
   
24 
 
session. Three phone interviews conducted by DA occurred between July 16, 2014 and 
July 25, 2014. Each participant received a $25 gift card and a parking voucher (if 
attended a focus group). All study procedures were approved by the UMMS Institutional 
Review Board. 
Data Processing and Analysis 
Audio recordings of the focus groups and the phone interviews were recorded and 
transcribed verbatim. The data from the transcripts were coded by the author of this paper 
using Microsoft Excel (version 7) and analyzed using a constant comparative method to 
identify key themes in the data.[50]   
Results 
Of the 21 consented participants, two participants did not successfully complete 
enrollment and were thus withdrawn from the study population. Of the remaining 19 
participants, 13 attended a focus group, 3 completed a phone interview, and 3 were lost to 
follow-up. Demographics of the 16 participants (6 T1D, 10 T2D) who completed the 
study are shown in Table 2.1. The majority of patients were between 40 and 70 years old, 
had at least a high school education, and had Internet access at their homes. Key findings 
of the study are summarized in Table 2.2 and described below.  
Perceived Ease of Use 
All participants (n=16) reported that the meter was easy to use when checking 
their blood glucose. The majority of participants (n=12) reported that the cellular-enabled 
glucose meters significantly eased the process of uploading their SMBG recordings. 
Several participants also described the touch screen interface as being well-designed and 
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intuitive (n=7). With regards to the diabetes care support program, some participants 
appreciated the convenience of interacting with a CDE through their preferred method of 
communication, either by telephone, email or through the meter (n= 6).  
Perceived Usefulness 
 Participants identified several functions of the meter they found useful. The 
automatic uploading of the SMBG levels was identified as being particularly helpful 
among those who previously uploaded through a computer manually (n=2) and those 
who only uploaded during their clinical appointments (n=10). “I like the upload feature 
because I never uploaded anything before because I thought it was too much of a hassle 
so, I like that part.” (60 year old, male, T2D) The automatic uploading also cultivated an 
“internal competition” within some of the participants (n= 4) as they acknowledged 
wanting to improve their blood glucose levels because they knew a CDE was monitoring 
their recordings, thus holding them more accountable. “I think the reason for that may be 
that I am competitive and I know it’s uploaded and looked at by people.” (65 year old, 
male, T2D) 
 Several other features of the meter were identified as being helpful, including the 
ability to add context with tags about meals, medications, and how they were feeling 
when they tested their blood glucose. Participants (n=10) also appreciated the helpful tips 
that automatically displayed on the meter after testing. “I like the tips that were on there 
after the blood sugar recording came out. I’ve never seen that before and I like it.” (51 
year old, female, T2D) The ability to track their recordings through the trends function 
was also identified as being useful (n=8). “That’s another thing that I liked. You can go 
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back and look at everything, and it will show you what it was on a certain day.” (51 year 
old, female, T2D) One participant found the sharing of SMBG functionality to be 
especially helpful. Using the “MyFamily TEAM” function on the meter, his mother 
received a text message containing his SMBG results after each testing. The participant 
acknowledged that this reduced the amount of time they spent talking about his routine 
diabetes management and that his mother appreciated receiving the notifications for each 
result, allowing her to monitor her son’s SMBG readings from afar.  
“One feature that I really did appreciate and I think much more so because I am 
new to this is there’s a feature that whenever your blood sugar is above a certain 
level or below a certain level it can send a message to not just the staff but I had 
my mom who has been in town receive a message so, she actually set the message 
so that when it was below 100 or above 101, so she got all of them.” (19 year old, 
male, T1D) 
All participants reported that additional support provided by the CDE coaches 
monitoring their SMBG recordings was, or would be in the case of those who didn’t 
interact with the CDE, very helpful. While the degree of interaction with the CDEs 
varied, several participants (n=7) acknowledged a feeling of reassurance that resulted 
from the additional layer of support available to them through the program. One 
participant, a male who had recently become a widow, stated that knowing someone else 
was watching over him filled a void created when his wife passed away.  
“The one feature I really like about it is that I am recently widowed so I live alone 
and like you said if your blood sugar goes low, there is somewhere there calling 
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me to make sure you are ok, and if you need help or whatever, so I really like that 
feature.” (63 year old, male, T1D)  
One participant reported that after disclosing to the CDE his difficulties 
maintaining an appropriate diet when his wife was out of town, the CDE provided him 
with healthy recipes that he was able to make for himself.  
“She said your levels are good but would you like to talk to me? and I said yea. 
And we got on the phone and talked for quite a bit of time about my diet and what 
would be good stuff for me to have that I’m not eating and she sent me an email, a 
whole menu for the last 2 weeks.” (65 year old, male, T2D) 
 Other participants had frequent interactions with the CDEs and relied on them for up to 
daily support.  
“The first time she actually she called me because the first time I got my meter my 
sugar was 237 and instead of hitting I was fine, I was stressed and she was on the 
other end of the phone, trying to find out why. Basically, we then started  
communicating with emails back and forth with diet suggestions and what to cut 
out, what not to do, what to try and change and to this day she said after this is 
done, if you need it ask. Just email me.” (41 year old, female, T1D) 
There were several occurrences reported where a CDE contacted a participant in 
response to a concerning SMBG level to provide support and education (n=10). In one 
case, a participant stated that her low sugar level caused a state of confusion that was 
alleviated after a CDE called and reminded her to drink juice.  
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“My blood sugars were running low, they were extremely low, and they contacted 
me. And I thought their advice was good. They kind of walked me through, if your 
insulin level is low you get mentally confused, and by them contacting me, it kept 
my focus and I did better than what I would have on my own.” (68 year old, 
female, T2D) 
Another example of care intervention occurred when a CDE called a participant in 
response to a dangerously high glucose level and realized the participant was in a state of 
confusion. The CDE contacted the participant’s provider, who called the patient and 
directed her to come to the clinic to receive attention. When asked about the urgent 
attention she received during a phone interview, the participant acknowledged that the 
care she received was initiated by the CDE and stated that she would have probably 
waited a few days to receive care during her scheduled appointment.“Yeah my sugars 
were very high so the doctor got the message and told me to come in. So I went in, they 
gave me treatment and it regulated my sugar.” (68 year old, female, T2D) 
External Factors 
Several factors external to the meter and program influenced the participants’ 
perceived ease of use and usefulness. Primarily, the technological literacy of participants 
prevented some from attempting to utilize certain functions. One participant knew that 
his SMBG recordings were being sent to a CDE but was unsure how they were being 
automatically uploaded after each time he tested. “I really don’t understand the whole 
uploading process so I’m sorry.” (71 year old, male, T2D) 
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Other participants, who identified as being technologically adept, were satisfied 
with the meter’s functional performance but offered potential improvements, including 
adding functionality for the meter to pair with insulin pumps, wireless internet 
compatibility for supplemental connectivity in areas with poor cellular reception, and 
improved SMBG tagging to allow for more detailed and customizable data with which to 
tag each recording.  
“Maybe you can add a few things to the notes instead of being limited to pushing 
buttons. Like it said I feel fine, not feeling well, stuff like that but maybe add 
something other than “other”, so you can type in how you feel in your own 
words.” (53 year old, male, T1D) 
Another common theme identified was that a lack of free time hampered the 
amount of effort participants were able to spend “playing around” with the meter or 
reading through the user manual. A few participants expressed regret that they did not 
utilize the meter and program to their full capabilities and thought an additional brief 
tutorial or training that described the different functions and features would be helpful 
(n=4).  
“I think there were things on here that I could have utilized better if I had known 
more about it. So I think just to be educated on the meter a little bit would have 
been beneficial.” (51 year old, male, T2D) 
 
Overall Experience and Value 
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When asked to evaluate their overall experience using the meter and participating 
in the program, every participant replied that their overall experience was positive and 
that they would recommend the meter and program to a friend or family member.  
“I like that there is a coach on the other end if something goes wrong, and the test 
strips are the perfect size, you don’t have to sit there and fight to get them out. 
And it’s just nice that I don’t have to plug a tiny little meter into my computer.” 
(41 year old, female, T1D) 
The majority of participants (n=14) also said they would like to continue using the 
meter and would stay in the program if it was provided by their health insurance. When 
asked if they would pay out of pocket to continue receiving the services, which included 
unlimited test strips, several said they would if the price was comparable to what they 
currently pay out of pocket for test strips. This value ranged from $20 to $50 per month. 
Discussion. 
This pilot study demonstrated that patients with diabetes are interested in 
participating in a CDE-delivered diabetes care support program facilitated by cellular-
enabled glucose meters. Among the participants who completed the study, most reported 
that the support program and cellular-enabled meter were both easy to understand and 
useful in the management of their diabetes.  
Patient acceptability has been demonstrated by evaluating perceived ease of use 
and usefulness. If a patient thinks something useful, and it is easy to use, there is a greater 
chance the patient will use that tool to manage their health. Prominent evaluation 
frameworks[51] posit that the impact of an intervention is a product of its reach and 
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effectiveness. Without high patient acceptability, the reach of an intervention will be low. 
This would be particularly true if the perceived effectiveness of the intervention is also 
low. Our study found that overall acceptability of a diabetes care support intervention 
facilitated by cellular-enabled glucose meters was very high. This suggests that this type 
of intervention may be an important component of a multi-faceted care delivery program 
for patients with diabetes.  
Potential for benefits such as improved patient treatment satisfaction, 
communication between patients and their care team, and the continuity and coordination 
of care delivery were also observed in this pilot study. During the study, patients were 
provided with additional tools to manage their diabetes and CDE support. Study 
participants acknowledged that both the support program and the cellular-glucose meter 
were very helpful. Providing patients with useful tools and support to help manage their 
diabetes can have a great effect on overall treatment satisfaction. Treatment satisfaction 
has been shown to be associated with diabetes-related outcomes.[52] The CDEs from the 
support program also provided an opportunity for additional and improved 
communication between the participants and their care team. The effects of patient-
provider communication on physiological, behavioral, and overall health status outcomes 
for patients with chronic diseases are well established.[53] Furthermore, there were 
instances where the CDEs served as a bridge of interaction between the patient 
participants and their specialty care team. This included specific instances where the 
CDEs recommended providers to follow-up with certain participants who had uploaded 
dangerously high or low blood glucose levels. This additional coordination between 
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CDEs resulted in participants visiting the clinic in order to receive medical attention or to 
have their medications and insulin doses adjusted. By doing so, some participants 
possibly averted a future visit to the emergency room, suggesting that this care support 
program could also have cost-saving implications.  The largest expenditure component of 
the estimated $245 billion total yearly cost of diagnosed diabetes is hospital inpatient 
care.[1]  The extent to which this type of intervention can improve patient-centric, 
clinical, and economic outcomes is worthy of further investigation.  
As we evaluated patient acceptability of both a support program and a glucose 
meter, we found that it is important to consider the variation in skills and capacities 
across the targeted patient populations. While the majority of participants reported that 
both were easy to use and useful, there were still differences in the degree of difficulty 
reported by the participants. Some reported that they experienced a little difficulty 
understanding how to best utilize all functionality presented to them while others 
simultaneously reported that the technology may have been too simple or that not enough 
functionality was provided. While we did not intentionally sample to highlight such 
differences, this demonstrates the wide range of skills and expectations patients have for 
using technological interventions to manage their health and the importance of 
considering variation in skills and capacities in future work.  
Strengths and Limitations 
This pilot study offers several strengths. We were able to recruit our targeted 
cohort in a short timeframe, which demonstrated the appeal of the intervention to patients 
with diabetes. We were also able to collect feedback from the majority of participants and 
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used an established framework to guide our qualitative evaluation of patient acceptability. 
There were also limitations of this study. The study population was predominantly white 
and well-educated. This is particularly concerning when studying acceptability to 
technology because this population may have greater exposure to technology and their 
experiences may not be representative of the general population. All subjects were also 
receiving care at a specialty diabetes center of excellence by endocrinologists. It will be 
important to evaluate acceptability in a larger, more diverse study population over a 
longer time period. We also sought feedback from patients with both type 1 and type 2 
diabetes but due to scheduling conflicts within the study group we were unable to 
separate patients into groups exclusive to their type of diabetes. The endocrinologist who 
sat in on focus groups was the clinician of a small number of the patients participating in 
the focus group.  The extent to which this affected the reporting of participants is 
unknown. Also, a few participants did not enroll or did not return for a focus group and 
could not be reached for a telephone interview. This loss of participant feedback is an 
important limitation to consider when evaluating patient acceptability because lack of 
participation may be associated with decreased acceptability of the technology and 
program. Qualitative coding was also only conducted by 1 coder. While the framework 
used to guide this study was chosen intentionally for its simplicity, other frameworks 
such as the Unified Theory of Acceptance and Use of Technology (UTAUT),[54] may 
have highlighted additional factors contributing to patient acceptability, such as social 
influences, that are important to consider.  Lastly, the SMBG data uploaded to the patient 
portal required manual transfer into the DCOE electronic health record. We collected no 
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specific data on this process so we are unable to confirm that this data transfer method 
would be feasible on a larger scale.  
Conclusion 
The data from this qualitative study showed a high level of patient acceptability to 
a diabetes support program facilitated by cellular-enabled glucose meters, as determined 
by patient-reported perceived ease of use and usefulness of the intervention. In addition 
to being easy to use and useful, examples of effectiveness of the intervention were 
described by participants. While overall satisfaction with the technology was high across 
all participants, a range of comfort and ability to utilize all functionality and /or desire for 
additional functionality still existed. 
 
 
 
 
 
  
   
35 
 
Figure 2.1. The Technology Acceptance Model 
 
Table 2.1. Demographic characteristics of GIT-1 participants. 
 Total n = 16 
Age (years), n (%) 
18-39 
40-49 
50-59 
60-69 
70+ 
 
1 (6.3) 
4 (25.0) 
4 (25.0) 
6 (37.5) 
1 (6.3) 
 
Gender, n (%) male 10 (62.5) 
 
DM Type, n (%) Type 1 6 (37.5) 
 
Time since DM Diagnosis, mean (sd) years 12.9 (10.4) 
 
Education, n (%) 
HS Grad 
Some College 
College Grad 
Some Post Grad 
 
5 (31.3) 
4 (25.0) 
4 (25.0) 
3 (18.7) 
 
Internet Access at Home, n (%) 15 (93.8) 
 
Internet Use, n (%) 
Once a week or less  
Several times a week 
Every Day  
Several times a day 
 
2 (12.5) 
2 (12.5) 
4 (25.0) 
8 (50.0) 
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Table 2.2. Key Findings of GIT-1  
Cellular-Enabled  Glucose Meter 
Themes Findings Exemplar quotations 
Ease of Use  Identified as easy to use:  
• the meter (in general)  
• testing process similar to other 
meters previously used 
• well-designed touch screen 
interface  
• automatic uploading after testing  
Testing Process: “I really enjoyed using the 
meter, I mean it’s so easy. And the amount of 
blood you need to test is really minimal.” 
Touch Screen Interface: “I loved the interface, it 
was great. The keys were big, it was good and 
easy to see.” 
 
Automatic Uploading: “For the most part, when 
I had a good cellular connection, the uploads 
worked seamlessly” 
 
Usefulness Identified as useful:  
• automatic uploading of the SMBG 
recordings  
• ability to tag details about meals, 
medications, and how they were 
feeling when they tested  
• helpful hint messages sent after 
testing 
• sharing results with family 
members 
• trends function 
SMBG Tags: “I like the fact that it gave you a 
bunch of options of how you are feeling so you 
can decide which is the best option to check off. 
And then it gives you the option of telling where 
it was, was it before dinner, after dinner, and 
same with the rest of the day.” 
Tips/Encouragement Messages: “I liked that 
every time after you uploaded a blood sugar it 
would send a message, you know “you’re in 
range… you’re low… you should monitor for 
signs of low blood sugar” ” 
 Sharing SMGB Recordings: “One feature that I 
really did appreciate, and I think much more so 
because I am new to this, is that whenever your 
blood sugar is above a certain level or below a 
certain level it can send a message to, not just 
the staff, but I had my mom receive a message” 
 
Trends Function: “I felt competitive. I wanted 
my trends to go down so my readings went a lot 
lower than they did with my old meter.”  
Areas of 
Improvement 
Identified areas of improvement:  
• ability to pair with insulin pumps 
• improved cellular reception 
• wifi compatibility 
• additional SMBG tagging options 
• brief tutorial to describe functions 
Insulin Pump capabilities: “The only other thing 
I would like to see is it communicate with my 
pump” 
Wifi connectivity: “So maybe adding like a wifi 
connectivity into this would be helpful in the 
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of meter 
• improved functional performance 
of meter to reduce screen freezes 
and time required to test blood 
• enhanced reminder features 
• better travel cases provided 
next generation” 
Customizable SMBG tags: “Maybe you can add 
a few things to the notes instead of being limited 
to pushing buttons like it said I feel fine, not 
feeling well, stuff like that, maybe add 
something other than “other”, so you can almost 
type in” 
Improved Functional Performance: “I think the 
meter itself could be faster.” 
Enhanced reminder functionality: “I’d say the 
only improvement I would make would be on 
the reminders. One of my old meters would 
sound off at a certain time, when it’s off. This 
one doesn’t do that. It only sounds off when the 
meter is on.” 
Training of all features: “I think there were 
things on here that I could have utilized better if 
I had known more about it. So I think just to be 
educated on the meter a little bit would have 
been beneficial.” 
 
External 
Factors 
Additional factors identified as 
impactful:  
• technological illiteracy prevented 
patients from utilizing full 
functionality 
• lack of free time prevented 
participants to explore 
functionality  
Technological Literacy: “I’m sure there is more 
that I could have done with the meter then I did 
just because I was confused about it. Not 
because the meter was confusing, I was 
confused.” 
Diabetes Care Support Program 
Themes Findings Exemplar quotations 
Ease of Use  Identified as easy to use:  
• interacting with CDE coach 
through preferred method of 
communication 
 
Interaction with CDE coach via preferred 
method: “I’m on the go all the time and it’s just 
easier to get it if I’m not right in the middle of 
something. She would email me and then I 
would respond and then she would respond to 
me later, so we were able to interact that way. I 
just feel it was easier that way because of my 
schedule.” 
 
Usefulness Identified as useful:  Reassurance from CDE coach monitoring: “Oh 
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• Continuous monitoring of SMBG 
recordings by CDE coaches 
• In-the-moment support provided 
by CDE coach 
• CDE coaching  sessions and 
provision of diabetes-related 
education 
• CDE coach interacting with 
provider 
• Portal dashboard to monitor 
SMBG trends 
it felt great, knowing that someone was on the 
other end keeping an eye on what I have done 
and how bad or good I’ve done. 
In-the-moment Support from CDE coach: “My 
blood sugars were running extremely low and 
they contacted me. And I thought their advice 
was good. They kind of walked me through it. If 
your insulin level is low you get mentally 
confused, and by them contacting me, it kept my 
focus and I did better than I would have on my 
own.” 
Education from CDE coach: “She would call and 
tell me what to do and how to go about it. She 
would put things on my email address and 
different things I should do or try to do to bring 
my counts down.” 
CDE coach as bridge to care team: “It was a 
couple weeks there when in the mornings I was 
having a lot of low readings. They contacted me 
and we talked. They ended up calling my doctor 
and discussed it with him and he called me to 
change something on my pump to rectify it and 
it was taken care of right away, rather than 
waiting to see him again in 3 or 4 months or so” 
 
Areas of 
Improvement 
Identified areas of improvement:  
• brief tutorial to describe features 
of program 
Program tutorial: “I think, a tutorial might help, 
might be useful.” 
External 
Factors 
Additional factors identified as 
impactful:  
• lack of free time prevented 
participants to explore all features 
of the program 
Time restrictions: “I think there might have been 
a place on the website where it said would you 
be interested in hearing from a coach so I 
pressed that button and they sent me a couple of 
emails trying to schedule a time but I’ve just 
been busy so that never actually happened”  
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CHAPTER III 
GET IN TOUCH – PHASE 2 PRELIMINARY RESULTS:  
EVALUATING FEASIBILITY AND EFFICACY OF A DIABETES CARE 
SUPPORT PROGRAM FACILITATED BY CELLULAR ENABLED GLUCOSE 
METERS 
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Abstract 
Background  
Patients with poorly-controlled type 2 diabetes (T2D) often struggle with the 
management of their diabetes. Technological interventions can help these patients by 
providing them with easily accessible tools and timely support from health care 
professionals.  
Aims  
 The aims of the Get In Touch – Phase 2 (GIT-2) study were to evaluate feasibility 
and efficacy of a diabetes care support intervention facilitated by cellular-enabled glucose 
meters in adults with poorly-controlled T2D.  
Methods 
GIT-2 was a 12-month randomized crossover trial involving adults receiving care 
at a diabetes specialty clinic with two Hemoglobin A1c % (A1c) levels greater than 8.0 in 
the previous 12 months. Enrolled participants were randomized to receive the 
intervention or usual care for the first 6 months of the study, followed by a crossover of 
treatment groups for the final 6 months of the study. The intervention included 
enrollment in a diabetes care support program run by Certified Diabetes Educators 
(CDEs) and facilitated by cellular-enabled glucose meters. The cellular-enabled glucose 
meters automatically upload self-monitored blood glucose (SMBG) recordings to a 
secure patient portal, allowing intervention CDEs to monitor and provide support when 
uploaded SMBG recordings are flagged as being high or low. Questionnaire data were 
collected at baseline and 6 and 12 months post enrollment. A1c labs were recorded at 
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enrollment and 3, 6, 9, and 12 months post enrollment. Aims 2 and 3 of this dissertation 
examine results from the first half of GIT-2 (from study enrollment up to treatment 
crossover at 6 months post enrollment).  
Results 
This study population (n=120) of patients with T2D was on average 56.7 years 
old and 52.5% were women.  Mean baseline A1c levels were 10.3 (SD=1.4) for the 
intervention group (n=60) and 10.0 (SD=1.4) for the control group (n=60).  
 The predicted mean change in diabetes treatment satisfaction was 2.3 points 
greater for the intervention group compared to the control group (p=0.09). Intervention 
participants experienced greater improvement in A1c of 0.41 from baseline to 3-months 
(p=0.12) and 0.38 from baseline to 6-months (p=0.16) compared to control group 
participants.  
Discussion 
Improvement in treatment satisfaction and A1c were seen by both groups, but 
showed signal of greater improvement for those participants receiving the intervention. 
The diabetes support program facilitated by cellular-enabled glucose meters displayed 
potential to improve diabetes-specific outcomes in this study. Significant improvements 
seen by patients of both groups suggest that increased engagement with their clinical 
team, as was required by the study protocol, can result in improved diabetes health 
outcomes. Future studies should look at the long-term effects of technological 
interventions that support both in-the-moment and scheduled support provided by care 
teams.  
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Background 
The American Diabetes Association estimates over 29 million Americans had 
diabetes in 2012 with 1.4 million new diagnosed cases every year. Diabetes is the 7th 
leading cause of death and cost over $245 billion to treat in the US in 2012.[55] Patients 
with poorly-controlled diabetes, as indicated by an increased A1c, have even higher 
morbidity and mortality[56] and greater cost to treat.[57] To address the growing diabetes 
crisis, additional support should be provided to those experiencing difficulty with the 
management of their disease.  
Patients with poorly-controlled diabetes struggle with their health management 
demands. To address these demands requires a significant degree of ‘patient work’.[6] 
The work required for patients with diabetes to manage their health includes daily 
medications, self-monitoring of blood glucose levels, and administration of insulin. 
Effective management of diabetes can also require active carbohydrate counting, physical 
activity tracking, and responsive insulin bolus administration. Regular and frequent 
interaction with the patient’s care team is also an important element of the management 
process. Diabetes care should be responsive to the patient’s health status and work 
demands but also proactive in attempting to improve patient self-management skills, 
disease knowledge, and engagement with their health maintenance. 
 To help patients with poorly-controlled diabetes, additional support, education, 
training, and tools should be provided to help manage their health. Previously successful 
diabetes programs have used technology to improve the support for patients with poorly-
controlled diabetes.[39, 58-62] These programs help by providing diabetes education, 
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self-management training, disease counseling, coaching, and additional support. Some 
programs provide support by having patients track PHI, such as blood glucose levels, and 
share it with members of their health care team. This allows the health care team to 
review detailed historical information and respond accordingly, depending on their role in 
the care team. Example of this response could include adjusting their treatment or 
medications plans, providing tailored education and counseling, or triaging to an 
appropriate care team member for additional follow-up depending on whether the care 
team member is a physician, nurse, pharmacist, CDE, or other health professional.  
Previously, collection of PHI by patients was usually completed with hand-
written logs. Sharing of that data occurred only during in-person encounters. Electronic 
logs, particularly those built into personal health records offered by a health care provider 
(also referred to as patient portals), allow patients to upload and share PHI data over the 
Internet. Data uploaded into patient portals are increasingly being made accessible to 
providers through patient portals tethered with electronic health record systems. This 
presents the opportunity for care teams to provide tailored support based upon data made 
available without requiring in-person encounters with patients.  
Using PHI data uploaded by patients to tailor and improve diabetes care faces 
several barriers, both by patients and health care teams. On the patient side, they could 
lack the technical ability or the physical hardware (ie – computers) to execute a data 
upload. Patients may also lack the motivation or available time required to upload and 
share PHI. These barriers are specifically true for patients with diabetes, as uploading 
SMBG data from personal glucose meters has historically required plugging the device 
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into a computer and manually executing an upload. Cellular-enabled glucose meters 
eliminate several barriers by automatically uploading SMBG recordings immediately 
upon being taken. This allows for SMBG data to be made accessible to patients, their 
care team, and caregivers without creating any additional patient work to execute the 
upload.  
In addition to easing patient work burden, automatic SMBG uploading also allows 
presents the opportunity for additional support to be provided in response to the uploaded 
data. A major provider-facing barrier for this service is the effort required to monitor and 
react to PHI data uploaded in real-time. While health care systems may not have the 
resources to pay physicians or nurses to monitor uploaded SMBG data in real-time, other 
health professionals, such as CDEs, may be a more affordable option. CDEs can provide 
responsive support and tailored education to patients after they test and upload SMBG 
recordings flagged as being high or low and serve as a bridge connecting the episodic 
encounters between patients and their usual care teams. This type of real-time, diabetes 
care support, provided by CDEs and facilitated by the automatic uploading of SMBG 
data by cellular-enabled glucose meters, has yet to be evaluated in a clinical setting of 
patients with poorly-controlled T2D. 
Aims 
The objective of this study was to conduct a preliminary evaluation of the 
feasibility and efficacy of the GIT-2 study. GIT-2 was a 12 month, randomized controlled 
crossover trial involving 120 participants with poorly-controlled T2D. In this paper, we 
evaluated preliminary data collected during the first half of GIT-2 (from enrollment to 
   
45 
 
treatment crossover). The goal of Aim 2 was to evaluate the feasibility of the intervention 
by examining change in patient-reported diabetes treatment satisfaction. The goal of Aim 
3 was to look at efficacy of the intervention by evaluating change in A1c from baseline to 
the 3-month and 6-month follow-up periods.  
Methods 
Setting, Sampling and Recruitment 
Patients with type 2 diabetes were recruited at the University of Massachusetts 
DCOE. The goal of the DCOE is to provide care to people with diabetes by coordinating 
a collaborative network to deliver comprehensive, patient-centered, high quality 
treatment. The DCOE is located in Worcester, MA and actively serves over 7,000 adults 
with diabetes.  
Inclusion criteria included the ability to speak English and having T2D with two 
consecutive A1c recordings greater than 8.0 over the previous 12 months at the time of 
recruitment. Patients were excluded if they were cognitively impaired, pregnant, or 
prisoners. Daily assessment of inclusion criteria for all patients scheduled for routine 
appointments at the DCOE was conducted. Eligible patients were approached in the 
waiting room by research assistants to explain the details of the study. To enroll in the 
study, interested participants signed the study consent forms, had a baseline A1c lab 
drawn, and completed a baseline survey. Recruitment of participants took place from 
4/1/2015 to 7/9/2015. 
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Randomization 
A randomization table was created prior to the start of recruitment using the 
RAND function in Microsoft Excel (2007) to equally allocate 120 participants to the 
treatment groups. Study staff not involved with recruitment created enrollment folders for 
each participant based upon the randomization table. Study staff members responsible for 
recruitment were blinded to treatment group designation from study enrollment through 
baseline survey administration. The only difference between treatment group enrollment 
folders was the intervention-designated folders contained an additional question and 
information about the intervention on the last page of the baseline survey. For 
participants randomized to the intervention group, the last baseline survey item asked if 
they would like to schedule a tutorial to provide more information about the program and 
instructions on how to use the cellular-enabled glucose meter. If answered yes, study staff 
scheduled a time to call the participant approximately 7 days later, after the expected 
delivery of a start-up package in the mail containing the cellular-enabled glucose meter 
and necessary meter materials such as testing strips and lances.  
Data Collection  
Upon study enrollment, all participants had a study-specific A1c lab drawn at the 
UMass Memorial Ambulatory Care Center. Participants were scheduled to return at 3, 6, 
9 and 12 months ±1 week post-study enrollment for quarterly A1c follow-up labs. 
Participants completed a baseline, 6-month, and 12-month survey. All surveys were 
completed by pen and paper. Participants were asked to complete the survey at the clinic. 
Participants were allowed to finish baseline surveys at home and mail them back, when 
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necessary. Data from the surveys were collected and managed using REDCap electronic 
data capture tools hosted at University of Massachusetts Medical School.[63]   
Primary Outcomes 
Aim 2: Evaluating feasibility by change in Diabetes Treatment Satisfaction. 
Change in patient-reported diabetes treatment satisfaction was the primary outcome used 
to assess feasibility of the intervention. Diabetes treatment satisfaction has been shown to 
be associated with positive diabetes outcomes.[52] To measure participant satisfaction 
with their diabetes treatment, the Diabetes Treatment Satisfaction Questionnaire (DTSQ) 
was administered at each survey.[64] The DTSQ is an 8-item survey that asks patients to 
rate their satisfaction from 1 (very dissatisfied) to 6 (very satisfied) on the following areas 
of their diabetes care: satisfaction with current treatment, feeling their blood sugars are 
unacceptably high recently, feeling their blood sugars are unacceptably low recently, how 
convenient their treatment is, how flexible their treatment is, how satisfied they are with 
the understanding of diabetes, how likely they are to recommend their treatment, and how 
satisfied they are to continue with the present form of treatment. To evaluate change in 
satisfaction attributable to the intervention, the Diabetes Treatment Satisfaction 
Questionnaire Change (DTSQc) was included in the 6-month follow-up and 12-month 
final surveys. The DTSQc is an 8-item survey that asks the extent to which participants 
experienced change in satisfaction over the course of the previous 6 months with 
responses ranging from much less satisfied now (-3) to much more satisfied now (3). The 
DTSQc, used in conjunction with the DTSQ, overcomes potential of ceiling effects 
encountered when only the status measure is used, allowing for interventions to show 
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greater value than possible with only the DTSQ measure being administered. To score the 
DTSQ and DTSQc, items 1, 4, 5, 6, 7 and 8 are added together for each scale. Item 2 
(perceived frequency of hyperglycemia) and item 3 (perceived frequency of 
hypoglycemia) are treated individually in data analyses.[64]  
Aim 3: Evaluating efficacy by change in A1c. Change in A1c was the primary 
outcome used to assess physiological efficacy of the intervention. A1c provides an 
estimate of blood sugar control over the previous 2-3 months and is the test of choice for 
the chronic management of diabetes.[65] A1c change was evaluated by comparing the 
mean changes in A1c from baseline to the 3 and 6-month follow-up visits between 
treatment groups. 
Covariates  
 Additional patient-reported covariates were collected in order to evaluate success 
of randomization by looking at baseline differences between treatment groups, to explore 
potential for mediation of intervention effects, and to conduct future exploratory 
secondary analyses. Included measures were selected to measure diabetes empowerment, 
patient activation, medication adherence, and social support and are described in greater 
detail below.  
Diabetes Empowerment. The Diabetes Empowerment Scale – Short Form (DES-
SF) is an 8 item self-report questionnaire created as a short form version of the original 
36-item Diabetes Empowerment Scale (DES). The DES-SF has shown to be a valid and 
reliable measure of diabetes-related psychosocial self-efficacy.[66] Responses for each 
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item of the scale are on a Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly 
Agree). A total score is calculated by averaging the scores of all the completed items.  
Patient Activation. The Patient Activation Measure (PAM)-6 is a short-form of 
the original PAM-22 measure. It assesses patient knowledge, skill, and confidence for 
self-management by asking patients on a scale from Disagree Strongly to Agree Strongly 
their level of agreement with a set of statements about the management of their 
health.[67] A summary score is calculated using a custom scoring sheet provided by 
Insignia Health (Portland, OR).  
Medication Adherence. The Morisky Medication Adherence Scale (MMAS)-8 
was used to assess medication adherence.[68] The MMAS-8 is an 8 item scale measuring 
medication adherence with scores ranging from 0 to 8. The first 7 items are yes/no 
questions where yes=1, no=0 in items 1-4, 6-7 and yes=0, no=1 for item 5. Item 8 is a 
five-point likert scale ranging in values from 0-4, which is then divided by 4 to 
standardize the item’s score to a maximum of 1 point. A total score of 0 indicates high   
adherence, 1-2 indicates medium adherence, and 3-8 indicates low adherence.  
Social Support. The 8-item modified Medical Outcome Study Social Support (mMOS-
SS) survey was used to assess social support. The mMOS-SS is a valid and reliable 
survey to measure social support in 2 subscales, emotional and instrumental social 
support.[69] A higher score indicates more support. To obtain a score for each subscale, 
the average of the scores for each item in the subscale is calculated. The overall support 
index is calculated by taking the average of all the 8 items and transform to a 0-100 scale 
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by the following formula: dividing (observed score-minimum possible score) by the 
(maximum possible score –minimum possible score) and multiplying by 100.  
Description of Intervention 
 All participants randomized to the intervention group received an In Touch 
cellular-enabled glucose meter and were enrolled in the Livongo for Diabetes 
program[70] for 6 months. The meter, testing supplies, and enrollment in the diabetes 
care program were provided by Livongo free of charge.  
The cellular-enabled glucose meter automatically uploaded all glucose recordings 
to a secure patient portal. Messages including feedback and tips designed to assist 
participants manage their diabetes were sent directly to the meter after each testing. These 
messages were developed using the American AADE National Standards for DSME 
curriculum. An algorithm selectively picked each message based on participant-provided 
data and the uploaded SMBG recordings. Other features of the meter included tagging 
SMBG recordings with important contextual information (before meal, after meal, 
neither, and how they were feeling at the time), tracking SMBG recordings with an 
electronic log book, and a built-in activity tracker. The meter also allowed participants to 
share SMBG data with anyone they designate as part of their care team (including their 
endocrinologist, primary care provider, caregiver, or family member) via text message, e-
mail, or fax.  
The Livongo for Diabetes care program is an accredited program by the AADE 
Diabetes Education Accreditation Program. The program includes both scheduled and in-
the-moment support provided by CDEs certified through the National Certifying Board 
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for Diabetes Educators (NCBDE). The CDEs monitored all flagged SMBG recordings 24 
hours a day and called participants the first time an uploaded blood glucose recording 
was above 250 mg/dL and greater than 400 mg/dL thereafter. The CDEs would also call 
participants if their SMBG recordings were below 40 mg/dL at any time during the study 
period. If an uploaded recording generated an alert for being too high or low, a CDE 
would contact the participant within 3 minutes of receiving the notification. After any call 
from the CDEs, participants were allowed to change the high or low threshold that would 
prompt a call. The CDEs also provided support through scheduled coaching sessions 
delivered over the phone and via email, as requested by participants. All coaching 
sessions were based on the AADE’s 7 self-care behaviors; healthy eating, being active, 
monitoring, taking medication, problem solving, reducing risks and health coping.[48] 
While CDEs did not give participants medical advice or make changes to their care plans, 
they could answer diabetes-specific questions including topics such as nutrition and 
lifestyle changes and contact participants’ providers if they believed uploaded SMBG 
recordings or conversations with participants warranted intervention from the 
participants’ care teams.  
Sample Size Estimation 
The primary physiological outcome of this study was change in A1c. We 
anticipated the distribution of change in A1c from baseline to 6-months would 
approximate a normal distribution, allowing for the use of a standard t test to examine 
differences in mean A1c change between treatment groups. Assuming a 1.0 % difference 
in mean A1c change between treatment groups and a 1.5 SD in A1c change for both 
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groups, we needed 48 participants per group for 90% power at the p=0.05 level. 
Assuming a 10% drop out, 53 participants were required. A conservative approach was 
taken and resulted in the recruitment of 60 participants per treatment group. Sample size 
calculations were performed using SAMPSI command in Stata software version 13.1 
(StataCorp, College Station, TX). 
Analytic Plan  
 Bivariate comparisons of baseline characteristics between treatment groups using 
independent samples t tests for continuous variables were conducted to evaluate success 
of randomization. Baseline characteristics of the participants who failed to return for the 
quarterly A1c labs and follow-up surveys were compared against those who adhered to 
protocol by using independent samples t tests.  
The primary outcome used to evaluate intervention feasibility was patient-
reported diabetes treatment satisfaction. Paired-samples t tests were used to evaluate 
treatment satisfaction change within each treatment group. Independent samples t tests 
were used to examine differences in treatment satisfaction change between treatment 
groups. Linear regression models were also used to estimate the relationship between the 
intervention and change in treatment satisfaction. The crude regression model contained 
only the treatment group and change in treatment satisfaction variables. A second model 
was then constructed including patient demographic characteristics and patient reported 
covariates that had a p<0.20 difference between treatment groups in baseline bivariate 
comparisons. Demographic characteristics included age, sex, race, income, education and 
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use of the Internet. Patient-reported covariates included were patient activation, diabetes 
empowerment, and social support.   
The primary physiological outcome used to evaluate efficacy of the intervention 
was change in A1c. Differences in A1c recordings from baseline to 3 and 6 months were 
examined using paired samples t tests to evaluate change within each treatment group. 
Independent samples t tests were used to examine change in A1c between treatment 
groups. Intention-to-treat versions of these analyses were conducted using the last 
observation carried forward (LOCF) data imputation method. The effects of the 
intervention on A1c change over time were analyzed using repeated measures, mixed-
effects linear regression models. The primary model contained a group variable, a time 
variable (0, 3 months, 6 months), and a treatment-by-time interaction variable as 
independent variables. A secondary model also contained demographic characteristics, 
including age, sex, race, income, education, and use of the internet, and the patient-
reported covariates that differed between groups at baseline under the p<0.20 level. 
Patient-reported covariates included in the model were patient activation, diabetes 
empowerment, and social support. All statistical analyses were conducted using Stata 
software version 13.1 (StataCorp, College Station, TX).  
Results 
Of 195 eligible patients approached for recruitment, 123 (63%) expressed interest 
in participating (Figure 3.1). Three participants failed to successfully complete the 
enrollment process. Of the 120 participants enrolled, 119 completed the initial survey 
(intervention n=59, control n=60) (Figure 3.1). We evaluated the success of 
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randomization by comparing baseline A1c, diabetes treatment satisfaction, demographic 
characteristics and patient-reported covariates between treatment groups (Table 3.1). 
Mean baseline A1c levels were 10.3 (SD=1.4) for the intervention group and 10.0 
(SD=1.4) for the control group. Out of a highest possible score of 36, intervention group 
participants reported a mean treatment satisfaction score of 29.6 (SD=5.4) compared to 
28.4 (SD=5.2) for control group participants. Age at enrollment ranged from 23 to 84 
years old with an average age of 56.7 years. The study population was 52.5% women and 
66.6% white. No differences in patient-reported medication adherence were seen at 
baseline between treatment groups while participants in the intervention group reported 
slightly higher diabetes empowerment (p=0.07) and patient activation (p=0.10) and 
slightly lower social support (p=0.16) compared to participants in the control group 
(Table 3.1). 
Of the original 120 study participants enrolled, 92 (76.7%) completed the 6 month 
follow-up survey, 99 (82.5%) returned for the scheduled 3-month A1c lab and 96 
(80.0%) returned for the 6-month A1c lab. Those who did not return for follow-up visits 
had significantly higher baseline A1c than those who returned for the scheduled A1c labs 
within both groups (Table 3.2). Among those who did not return for a follow-up A1c lab, 
the number of participants, mean baseline treatment satisfaction, and mean baseline A1c 
did not differ between the intervention and the control groups (Table 3.2).  
Of the 60 participants who received the intervention, 26 (43%) requested and 
received a phone tutorial at the start of the study. Actual use of the meter varied within 
the group, with  27 (45%) participants using the meter on average more than once per 
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day, 26 (43%) participants using the meter on average less than once per day, and 7 
(12%) participants not using the meter at all.  Among the participants who used the 
meter, 23 were called at least once in response to their uploaded SMBG recordings with 
20 participants receiving support from a CDE. Of the 20 participants who interacted with 
the CDEs, 11 scheduled at least one additional coaching session. 
Change in Diabetes Treatment Satisfaction.  
Among participants completing the 6-month follow-up survey, intervention group 
participants reported an improved mean treatment satisfaction change score of 12.9 
(SD=5.6). This was in comparison to an improved mean treatment satisfaction score of 
10.7 (SD 6.6) for the control group (p=0.09). At the individual item level, 3 items of the 
DTSQc showed greater improvement in the intervention group compared to the control 
group. They were: satisfaction with current treatment (p=0.07), how convenient their 
treatment is (p=0.02), and how satisfied they were with their understanding of diabetes 
(p=0.04) (Table 3.3).  
Results from the multivariable linear regression models with change in treatment 
satisfaction as the dependent variable are shown in Table 3.4. In the primary model, 
intervention group participants showed a 2.3 unit greater improvement in diabetes 
treatment satisfaction score compared to control group participants (p=0.09). After 
accounting for age, sex, education, race, income use of internet, patient activation, 
diabetes empowerment, and social support, intervention group participants reported a 2.5 
unit higher treatment satisfaction change score than the control group (p=0.08).  
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Change in Hemoglobin A1c. 
Mean A1c for the intervention group were 10.3 (SD=1.4) at baseline (n=60), 8.8 
(SD=1.1) at 3 months (n=48) and 8.9 (SD=1.0) at 6 months (n=47). Mean A1c for the 
control group were 10.0 (SD=1.4) at baseline (n=60), 8.9 (SD=1.4) at 3 months (n=51) 
and 9.0 (SD=1.5) at 6 months (n= 49). Mean A1c improvement at 3 months was 1.3 
(95% CI: 0.8-1.7)) for the intervention group compared to 0.9 (95% CI: 0.5-1.3) for the 
control group (p=0.22) and at 6 months was 1.1 (95% CI: 0.7-1.6) for intervention group 
compared to 0.7 (95% CI: 0.3-1.1) for control group (p=0.14) (Table 3.5). Intent-to-treat 
analyses using LOCF imputation showed the change in A1c from baseline to 3 months 
was 1.0 (95% CI: 0.6-1.6) for intervention group participants compared to 0.75 (95% CI: 
0.4-1.1) for control group participants (p=0.34). Mean change from baseline to 6 months 
was 0.9 (95% CI: 0.6-1.3) for the intervention group compared to 0.7 (95% CI: 0.4-1.0) 
for the control group (p=0.46).  
A repeated measures mixed-effects linear regression model containing the 
treatment group, time, and treatment-by-time interaction as independent variables and 
A1c at baseline, 3 months, and 6 months as dependent outcomes showed that participants 
in both groups improved from baseline to 3-months (p<0.001) and maintained that 
improvement at 6-months (p<0.001). A1c was an estimated 0.41 greater improvement for 
Intervention group participants at 3 months and 0.38 greater improvement at 6 months 
compared to control group participants (p=0.12 and p=0.16, respectively) (Table 3.6). 
After accounting for demographic characteristics (age, sex, race, income, education, and 
internet use) and patient reported covariates (patient activation, diabetes empowerment, 
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and social support), intervention group participants had an estimated 0.45 greater 
improvement in A1c compared to the control group at the 3-month time point (p=0.12). 
This estimated difference in A1c improvement between the intervention and control 
group participants was 0.56 at the 6-month follow-up time point with intervention group 
participants seeing greater improvement (p=0.05) (Table 3.6).  
Discussion 
Feasibility and efficacy of a diabetes support intervention facilitated by cellular-
enabled glucose meters were assessed in a population of patients with poorly controlled 
type 2 diabetes. Significant improvements in diabetes treatment satisfaction and 
reductions of A1c were seen within both control and intervention groups with 
improvement in treatment satisfaction greater for intervention participants. In per-
protocol analyses, participants in the intervention group showed trends towards greater 
improvement in A1c compared to participants in the control group. Repeated measures 
mixed-effects model showed greater improvement of A1c from baseline to each of the 
follow-up time points for intervention group participants compared to the control group 
participants, albeit not at the p<0.05 statistical significant level. These results demonstrate 
the feasibility and potential efficacy of the intervention.  
  Similar interventions targeting patients with poorly-controlled diabetes have also 
shown potential to improve health outcomes for this increasingly prevalent and costly 
patient population.[18, 39, 58-62, 71, 72] Unique to this study is the in-the-moment 
support provided in response to low or high SMBG recordings uploaded instantly by 
cellular-enabled glucose meters. By contacting patients immediately after their 
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dangerously high or low blood glucose test results are taken, care teams can offer timely 
support when patients may need it most. They can also take advantage of a teachable 
moment to provide education and disease management training. Teachable moments have 
been described as times when patients are receptive to counseling, education, and 
discussions of lifestyle patterns, risk factors, or compliance.[73] During these teachable 
moments, care team members can help patients identify the reasons why their blood 
glucose is suboptimal at that time and advise on how best to prevent it from happening in 
the future.   
In this population of poorly-controlled T2D patients, we saw improvements in 
treatment satisfaction and A1c in both intervention and control groups. In addition to an 
observer effect bias, the increased amount of interactions between patients and care team 
members, as the study protocol required both groups to return for quarterly A1c labs and 
follow-up surveys(with reminder calls preceding each), could also result in positive 
outcomes. Previous studies have also found that patients with diabetes who fail to show 
for routine appointments have worse health outcomes, lower SMBG rates, and greater 
medication non-adherence.[74-76] This is supported by our finding that patients from 
both groups who failed to return for the follow-up visits had higher baseline A1c levels. 
Future studies should plan additional intervention activities to engage these patients who 
are at risk for being lost to follow-up. A possible solution would be to add a structured, 
scheduled coaching session component to encourage participation in the study while 
providing an additional opportunity to deliver diabetes self-management education. 
Similar program have shown to successfully improve health outcomes in this 
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population.[77] An alternative approach would be to involve caregivers in the 
intervention. In addition to encouraging their patients to engage in the study, providing 
caregivers access to patient’s uploaded SMBG recordings can improve the quality of 
support they are able to provide and reduce caregiver burden. The effects of this 
intervention on caregiver support and burden were not investigated in this study but 
should be considered in future work. 
 There were several strengths and limitations of this study. Strengths included 
recruiting an inflated sample size that adequately accounted for participant drop out 
allowing for power to detect a clinically meaningful difference in A1c change between 
groups to be retained. Other strengths included the collection of both physiological 
outcomes (A1c) and patient-reported outcomes (diabetes treatment satisfaction). The 
collection of patient-reported demographics and diabetes-specific covariates were also 
strengths of the study. Limitations of this study included the relatively short time frame 
of receiving the intervention (6 months) and the duration of diabetes per participant was 
not collected. These limitations are especially important considering the primary 
outcome, change in A1c, is a measurement for glucose instability over an extended 
period of time. Other limitations were that participants who failed to return for follow-up 
visits had higher baseline A1c levels than those who did return. This suggests additional 
efforts must be done to engage patients with very poorly-controlled diabetes.  
This intervention resulted in improved treatment satisfaction and health outcomes 
that approached being significantly greater than the improvements seen by the control 
group, demonstrating feasibility and efficacy potential. Next, we will analyze post-
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crossover effects for each group in order to evaluate intervention maintenance among 
intervention participants and intervention effects among the participants who first served 
as controls. Future studies should consider including a scheduled coaching component, 
involve the caregivers of patients, and invest additional efforts to engage sicker patients 
who are more likely to drop out of study activities.  
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Table 3.1. GIT-2 Study Population Demographics 
Characteristics Intervention n=59* 
Control 
n=60 p 
Age, mean(SD) 56.1 (11.1) 57.4 (12.1) 0.55 
Age Categories, (%) 
18-40 
40-65 
65+ 
 
8.3 
71.7 
20.0 
 
6.7 
65.0 
28.3 
 
 
0.56 
Gender, (%) 
Women 
 
 56.7 
 
48.3 
0.36 
Race, (%) 
White 
Black 
Hispanic Latino 
Native/Alaskan American 
More than 1 race 
Not Reported 
 
61.6 
10.0 
18.3 
1.7 
3.3 
5.0 
 
71.7 
5.0 
15.0 
0.0 
3.3 
5.0 
 
 
 
0.75 
Education, (%) 
<High School Grad 
High School Grad 
Post High School Trade  
1-3 years College 
College Grad 
Not Reported 
 
15.0 
30.0 
10.0 
23.3 
18.3 
3.3 
 
11.7 
28.3 
8.3 
26.7 
21.7  
3.3 
 
 
 
0.80 
Household Income, (%) 
<20k 
20-50k 
50-100k 
>100k 
Not Reported  
 
40.0 
18.3 
16.7 
18.3 
6.7 
 
36.7 
23.3 
18.3 
11.7 
10.0 
 
 
 
0.78 
 
Internet Access, (%) 
No 
Yes 
Not Reported 
 
15.0 
83.3 
1.7 
 
18.3 
78.3 
3.3 
 
 
0.73 
Internet User, (%) 
No 
Yes 
Not Reported 
 
28.3 
68.3 
3.3 
 
33.3 
63.3 
3.3 
 
 
0.84 
A1c %, mean (SD)* 10.3 (1.4) 10.0 (1.4) 0.21 
Treatment satisfaction, mean (SD) 29.6 (5.3) 28.4 (5.2) 0.24 
Diabetes empowerment, mean 
(SD) 
4.0 (0.6) 3.8 (0.7) 0.07  
Patient activation, mean (SD) 58.6 (13.4) 55.0 (10.0) 0.10  
Medication adherence, mean (SD) 2.8 (1.9) 3.1 (1.9) 0.24 
Social support, mean (SD) 26.1 (8.5) 28.5 (8.8) 0.16 
*n=60 in Intervention Group for baseline A1c %  
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Table 3.2. Baseline characteristics. Participants returned for 6-month follow-up per-protocol vs. 
those who did not return, by group 
 Intervention group Control group Did Not 
Complete 
 
IV vs. 
Control 
p 
Completed 
6-month  
Did Not 
Complete 
6-month  
 
 
p 
Completed 
6-month  
 
Did Not 
Complete 
6-month 
 
p 
 n=40 n=16  n=44 n=15   
Treatment 
Satisfaction, 
mean (SD)  
29.3 (5.6) 30.2 (4.8) 0.58 28.2 (5.3) 29.1 (4.9) 0.56 0.53 
 n=47 n=13  n=49 n=11   
A1c, mean 
(SD) 
 
10.1 (1.2) 11.1 (1.6) 0.01 9.7 (1.1) 11.3 (2.0) <0.001 0.88 
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Table 3.3. Change in Diabetes Treatment Satisfaction, by group 
 Intervention 
group 
Control group Intervention-
Control  
 n Mean 
(SD) 
n Mean 
(SD) 
Differenc
e 
p 
Baseline DTSQ 56 29.6 (5.4) 59 28.4 (5.2) 1.2 0.24 
6 Months DTSQ 41 31.1 (3.9) 45 29.4 (4.8) 1.7 0.07 
Change at 6 Months, Overall DTSQc 41 12.9 (5.6) 46 10.6 (6.6) 2.3 0.09 
Change at 6 Months, Individual 
DTSQc Items 
      
Satisfaction with current treatment 42 2.2 (1.1) 48 1.7 (1.2) 0.46 0.07 
Felt blood sugars unacceptably high 
recently 
41 0.93 (1.8) 48 1.1 (1.7) -0.16 0.67 
Felt blood sugars unacceptably low 
recently 
42 -0.38 (1.6) 48 -0.38 (1.8) 0.00 0.99 
How convenient treatment is 42 2.2 (0.8) 47 1.5 (1.4) 0.61 0.02 
How flexible treatment is 41 2.0 (1.3) 48 1.6 (1.4) 0.41 0.15 
How satisfied with understanding of 
diabetes 
42 2.3 (1.0) 48 1.7 (1.5) 0.56 0.04 
How likely to recommend treatment 42 2.1 (1.3) 47 2.0 (1.3) 0.12 0.66 
How satisfied to continue with 
present form of treatment 
42 2.2 (1.2) 48 1.9 (1.3) 0.34 0.20 
 
 
Table 3.4. Linear regression results predicting change in Diabetes Treatment Satisfaction  
Variable Coefficient  SE p 
Intervention  
Crude 
Full model*  
 
2.3 
2.5 
 
1.3 
1.4 
 
0.09 
0.08 
*Accounts for age, gender, education, race, income, internet use, diabetes empowerment, patient 
activation, and social support  
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Table 3.5. Change in A1c, by group 
 Intervention 
group 
Control Group Intervention - 
Control  
A1c % Results n Mean (SD) n Mean % Difference P*  
Baseline, mean (SD) 60 10.3 (1.4) 60 10.0 (1.4) 0.32 0.21 
3 month       
Per-protocol, mean (SD) 48 8.8 (1.1) 51 8.9 (1.4) -0.14 0.59 
Intention to treat, mean(SD)  60 9.3 (1.5) 60 9.2 (1.7) 0.08 0.80 
Change from Baseline to 3 month       
Per-protocol, mean  
(95 % CI) 
48 -1.3  
(0.81-1.69)a 
51 -0.88  
(0.47-1.30) a 
0.37 0.22 
Intention to treat, mean  
(95% CI) 
60 -1.0  
(0.63-1.37) a 
60 -0.75  
(0.39-1.11) a 
0.25 0.34 
6 month       
Per-protocol, mean (SD) 47 8.9 (1.0) 49 9.0 (1.5) -0.05 0.86 
Intention to treat, mean(SD) 60 9.4 (1.5) 60 9.2 (1.8) 0.14 0.64 
Change from Baseline to 6 month       
Per-protocol, mean  
(95% CI) 
47 -1.1  
(0.69-1.57) a 
49 -0.71  
(0.34-1.08) a 
0.42 0.14 
Intention to treat, mean  
(95% CI)  
60 -0.91  
(0.55-1.3) a 
60 -0.73  
(0.40-1.06) a 
0.18 0.46 
* independent-samples t test  
 a paired sample t test, significant at p<0.001 level 
 
 
Table 3.6. A1c Repeated Measures Mixed Effects Regression Results, Empty and Full Model  
Variable 
Crude Model Full Model* 
Beta Coefficient  SE p Beta Coefficient SE p 
Treatment 
Control (ref) 
Intervention 
 
 
0.32 
 
 
0.25 
 
 
0.20 
 
 
0.27 
 
 
0.25 
 
 
0.28 
Time 
Baseline (ref) 
3-mo visit 
6-mo visit 
 
 
-0.97 
-0.87 
 
 
0.19 
0.19 
 
 
<0.001 
<0.001 
 
 
-1.02 
-0.84 
 
 
0.21 
0.21 
 
 
<0.001 
<0.001 
Treatment x Time 
Intervention, 3-mo 
Intervention, 6-mo 
 
-0.41 
-0.38 
 
0.26 
0.27 
 
0.12 
0.16 
 
-0.45 
-0.56 
 
0.29 
0.29 
 
0.12 
0.05 
*Accounts for age, sex, race, education, income, internet use, diabetes empowerment, patient 
activation, social support 
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CHAPTER IV 
 CONCLUSIONS AND DISCUSSION 
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The overall purpose of this dissertation was to evaluate the acceptability, 
feasibility, and preliminary efficacy of a diabetes care support program provided by 
CDEs and facilitated by cellular-enabled glucose meters. To accomplish these aims, we 
conducted a multi-phase study at the University of Massachusetts Medical School DCOE. 
The first phase was a 1-month acceptability pilot involving patients with T1D and T2D. 
The second phase was a 12-month randomized crossover trial involving patients with 
poorly-controlled T2D. Preliminary results at the 6-month time point are reported in this 
dissertation.  
In the acceptability pilot, we found that patients with both T1D and T2D were 
generally satisfied with the care program and reported that the cellular-enabled glucose 
meter was both useful and easy to use. Participants particularly liked the automatic 
upload feature of the meter and the additional support provided by the CDEs. Important 
areas identified for improvement included providing additional training and education 
about the functionality of the meter. In the first half of the subsequent randomized 
crossover trial, we saw significant improvements in treatment satisfaction and A1c results 
for patients in both groups, with trends towards greater improvement in the intervention 
group when compared to the control group.  
Diabetes is a very complex disease with several patient health management 
demands that could benefit from innovative technological interventions.[78] Common 
barriers to utilizing patient-facing technology to manage diabetes include physically 
possessing the technology throughout the day, knowing how to operate, execute, and take 
advantage of different functions and services, and receiving positive endorsements from 
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providers who may doubt the benefits are worth the additional time, effort and 
uncompensated work that will be created for them.[40] We believe the Livongo for 
Diabetes support program and the In Touch cellular-enabled glucose meter addresses 
several of these barriers. By providing patients with cellular-enabled glucose meters as 
part of the intervention, the physical barriers of owning the equipment were addressed. 
The automatic upload feature of the cellular-enabled glucose meter eliminated the need to 
possess any additional equipment or to know how to execute a SMBG upload. The meter 
also had a user-friendly touch screen interface and used testing strips that were thicker 
and easier to handle than most strips currently available. The support program was also 
run by CDEs employed by Livongo, adding little additional burden on the regular clinical 
care team.  
Among the participants who completed the follow-up protocols, overall 
improvements were seen for both the intervention and control group. The design of this 
study may have contributed to this study effect. Per study protocol, participants from both 
groups were scheduled to return at 3 and 6 months for A1c labs and were called to 
remind them of their upcoming appointments. Increased frequency of encounters between 
patients and providers has been shown to lead to improved health outcomes for patients 
with diabetes,[79, 80] suggesting that efforts to engage patients may have significant 
health benefits. This is especially true if interventions can tailor the support to the 
patients’ level of activation. Patient activation has been defined as a patients’ willingness 
and ability to take independent actions to manage their health and care.[81] Providing 
flexible support that addresses the varying needs and preferences of patients and then 
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setting reasonable goals that are achievable by the patients has shown to result in benefits 
among patients with both high and low patients activation.[81]  
Tailoring support to meet the needs of patients is important to consider in the 
context of our study. To investigate the potential of the intervention, we recruited a 
population of patients with poorly-controlled diabetes. By selecting this specific 
population, the risk of successfully retaining participants in the study was heightened. 
This risk was demonstrated as the majority of those who failed to return for follow-up 
visits had significantly higher A1c levels at enrollment. As there were no differences 
among those who failed to be retained between treatment groups, it suggests that the 
intervention was equally unsuccessful at engaging these hard to reach patients as usual 
care was. To increase patient engagement and improve patient activation, future studies 
should tailor outreach and support so that it is amenable to all participants.  
Support provided by the CDEs in the intervention consisted of outreach in 
response to high or low SMBG recordings and through coaching appointments as 
requested by participants. While in-the-moment support may have been valuable to 
patients who tested high or low with the meter and scheduled support may have assisted 
patients who were activated enough to seek additional help, there was minimal CDE 
support delivered routinely to all patients receiving the intervention. Scheduled, periodic 
coaching sessions using telehealth technology have been shown to improve diabetes 
health outcomes and lower costs by reducing the number of in person visits.[42, 62, 82] 
Future studies should consider implementing scheduled coaching sessions with the CDEs 
to complement in-the-moment and requested support provided.  
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A key component to delivering health education and self-management training is 
taking advantage of teachable moments. Teachable moments are periods when patients 
are particularly receptive to counseling, education, or a simple discussion of lifestyle 
patterns, risk factors, or compliance.[73] In our intervention, the responsive support 
provided by the CDEs presented opportunities to take advantage of teachable moments 
that occurred immediately after a concerning SMBG level was recorded as patients may 
be more receptive to learning about their disease as they are experiencing complications. 
While other participants may have not been well enough at that moment to process 
information or counseling, the support call still provided the opportunity to schedule 
future coaching sessions and to have a tailored discussion regarding their recent 
experience. This support could also be particularly beneficial for patients who have 
recently been diagnosed, switched medications, are beginning administration of insulin or 
adjusting their insulin dosage. These patients will experience changes in their health 
status that may generate questions that are best answered immediately. Receiving this 
timely support could be very beneficial as shown by a recent telehealth intervention that 
effectively helped patients reach optimal insulin dose, resulting in higher treatment 
satisfaction.[82]  
There were several strengths and limitations to this study. Strengths included a 
mixed-methods approach consisting of both qualitatively evaluating the acceptability in 
patients with both T1D and T2D and quantitatively assessing feasibility and efficacy by 
conducting a randomized trial comparing the intervention to usual care received at a 
diabetes specialty clinic. To assess feasibility and efficacy, we used both patient reported 
   
71 
 
and physiological measures as the primary outcomes and collected data at baseline and at 
multiple follow-up periods. We believe the cross-over trial design was also a strength as 
it presented the opportunity for all participants to receive the intervention.   
In addition to positive acceptability, feasibility, and efficacy of the intervention 
from the patient perspective, an effective intervention must also fit into the clinical work 
flow of a care team in order for benefits seen to be sustainable. In the case of GIT-2, data 
from the cellular-enabled meters flowed directly into each patient’s EHR and intervention 
CDEs provided weekly reports on interactions with patients. Both of these intervention 
components were designed to improve the delivery of comprehensive, coordinated care 
without taxing the regular care team’s resources. This was an important strength of the 
intervention.  
A limitation of the study was the relatively small sample size who received the 
intervention over a limited period of time during GIT-2. This is especially limiting 
considering that the primary efficacy outcome, change in A1c, is a metric that averages 
the amount of blood glucose over a 3 month period of time. A longer time enrolled in the 
intervention may be required by some to see benefits in A1c. We also experienced a 
moderate loss of participants to follow-up, especially among those with very poorly 
controlled A1c levels. Because of the multiple components of the intervention, it was 
difficult to tease apart benefits seen due to the care support program and those resulting 
from using a technologically advanced glucose meter.  Furthermore, there was minimal 
data collected on the utilization of different functions on the meter for this analysis, 
restricting the potential to look at the benefits each function provided.  
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Next we will evaluate the data from the second half (post treatment crossover) of 
GIT-2. It will be particularly interesting to see if the benefits seen amongst the 
intervention group are maintained after they no longer have access to the cellular-enabled 
glucose meter and CDE support. It will also be interesting to see if benefits achieved by 
the control group are increased even greater upon receiving the meter and access to 
additional CDE support. Additionally, all study participants are provided with the option 
to continue in the program on a subscription payment ($25/month) basis. Monitoring the 
patients who choose to pay for the service out of pocket may provide additional insight 
into the long term effects of the intervention.   
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SUPPLEMENTARY MANUSCRIPT: 
THE PROMISE OF TELECOMMUNICATION TOOLS TO "REACH" THE 
DISENGAGED PATIENT WITH DIABETES. 
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Abstract 
Purpose of Review 
To discuss recent research on the use of telecommunication technologies to improve care 
for disengaged patients with diabetes. 
Recent Findings 
It is established that patients who are disengaged with their health care have worse health 
outcomes. Reasons for disengagement vary but could be due to difficulties accessing or 
affording care or not possessing the skills or tools required to manage their disease. New 
patient-facing technologies are being used to improve communication and coordination 
of care for patients with diabetes. Early results show improvements in health outcomes. 
Utilizing these technologies to reach patient groups susceptible for disengagement has 
begun to demonstrate improvement.   
Summary 
Research over the past year has continued to demonstrate the promise of using 
telecommunication tools to assist patients in the management of diabetes. While a few 
studies looked specifically at disengaged patients, efforts to utilize appropriate 
technological interventions targeting specific groups of patients are needed.  
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Introduction 
Diabetes Mellitus is a complex, chronic condition affecting over 29 million 
Americans and costing over $245 billion dollars in direct and indirect costs per year for 
diagnosed individuals. [83] Managing diabetes is very demanding of patients. 
Appropriate self-management requires a significant amount of time, energy, and 
discipline. Patients are required to make difficult behavioral changes in their diet and 
exercise habits. They often need to monitor their blood glucose levels and self-administer 
complex medication regimens. Effective self-management of diabetes requires a high-
degree of disease knowledge as patients must interpret their self-monitored blood glucose 
(SMBG) recordings and adjust their physical activity, diet, and medications accordingly.  
The demands of self-caring for diabetes are often overwhelming for patients.[84] 
Frequent interactions between patients and their care teams are required to answer 
questions, troubleshoot new situations, and make adjustments to their medications and 
care plan. While frequent interaction with care teams is recommended for most patients 
with diabetes, actual engagement is surprising low for many patients. Patients with 
diabetes that are disengaged with the management of their care have higher Hemoglobin 
A1c (A1c), anxiety, and depression levels.[85]The cost of medical care for disengaged 
patients with poorly controlled diabetes is ultimately greater as they more likely to 
require emergency services and have worse health outcomes with more co-
morbidities.[86, 87]  
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Reasons for disengagement 
There are several potential reasons, involving both extrinsic and intrinsic factors, for 
patients with diabetes to become disengaged with the management of their own 
health.[88] Access barriers include living in rural or low-income locations, having 
insufficient transportation or insurance coverage, or not being able to afford to pay for 
clinical visits and medications. Disengaged patients may also not have time available to 
regularly interact with their care team because they can’t afford to miss work, have 
trouble getting appointments that fit their schedule, or are too busy managing other 
personal, family, or co-morbidity obligations. Language barriers can also result in 
disengagement as non-English speaking patients may not understand their care plan or be 
able to effectively communicate with their care team.  
There may also be intrinsic reasons why patients are disengaged from their care team. 
Patients may not possess the appropriate attitude, knowledge, or skill set to effectively 
self-manage. They may be embarrassed about their health status or that they did not meet 
goals set with their care team or believe interacting with their care team may result in 
undesired negative feedback. There may be a perceived lack of value of regular 
interactions with their care team and missing appointments with no follow-up scheduled 
can lead to a prolonged absence from care. Males and younger adults have particularly 
shown to be more at risk of disengagement.[85] Previous studies have also shown that 
satisfaction with treatment and relationship with providers are both associated with 
adherence to treatment plans.[89] 
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Using telecommunication technologies to engage patients 
A potential solution to reach disengaged patients is to leverage emerging 
telecommunication technologies. This is particularly true for mobile-health (mHealth) 
interventions as 64% of American adults now own a smartphone.[90] Technological 
interventions could be particularly beneficial reaching young people as they are high 
users of technology while people of lower SES status and of non-white race are more 
likely to depend on their smartphone for Internet access.[90]  As technology becomes 
more entwined in the everyday lives of our population, the potential for leveraging its use 
for health promotion, disease prevention and management rises accordingly, especially 
for typically hard-to-reach, vulnerable populations of patients with diabetes.    
A promising technological approach to reach disengaged patients is to encourage 
the adoption and utilization of electronic patient portals. A patient portal is an online 
personal health records “tethered” with a healthcare provider’s electronic health record 
system, allowing patients to access and contribute personal health information (PHI), 
communicate with their care team, and utilize various tools to manage their health.[40] 
Functions available through a portal vary by healthcare organization but typically include 
access to PHI, secure messaging with care team, online appointment scheduling and 
reminders, requesting prescription refills, and provision of tailored health information and 
education. Patient portals serve as a valuable alternative to the traditional encounter with 
the health care system and may be particularly helpful for patients who are disengaged 
due to access difficulties such as a lack of time available or living in a rural location. 
There were several studies in the past year that examined patient portal use and its effects 
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in the management of diabetes.[91-93] This should be expected as the number of 
providers are offering more enhanced portal features in response to the meaningful use 
requirement of the Health Information Technology for Economic and Clinical Health Act 
(HITECH).[94]  
Additional telehealth interventions could be valuable for patients with access 
difficulties. Telehealth involves the use of audio, video, and other telecommunications 
technologies for the transmission of information and data relevant to the diagnosis and 
treatment of medical conditions, to provide health services or aid healthcare personnel at 
distant sites, and for health promotion and disease prevention.[95] Telehealth 
consultations via video, telephone, or e-messaging eliminate physical barriers of traveling 
to clinical appointments and can facilitate both regular and emergency consultations. 
Telehealth systems can also provide a means of secure transmission of patient self-
management data to web-based patient portals accessible to patients, caregivers, and care 
teams.  Access to this data improves the ability of providers to monitor patients’ health 
status and adjust care plans and medications without requiring patients to attend clinics in 
person. This is in contrast to traditional in-person care that requires patients to be more 
engaged and show up in person. Recent interventions that involve the sharing of patient 
self-management data to inform telehealth consultations with nurses, pharmacists, and 
certified diabetes educators have all shown varying degrees of benefits.[61, 96]. Health 
care that requires frequent assessment, for example wound care, may be particularly 
suited for telehealth monitoring.[97]  
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Patients who report experiencing trouble accessing health care services are more 
likely to use technology to search for health information.[98]  In addition to searching for 
and obtaining health information, the “Web 2.0” movement has created public and 
private platforms for patients to share and contribute their own health information.[99] 
Social media outlets such as Twitter or Facebook allow patients to access and publically 
post information while online social support groups and websites provide more private 
opportunities for patients to obtain health information and disease management support.  
While the potential roles of telecommunication technology interventions in health 
care are numerous, in this paper we focus on their potential to reach the difficult to treat 
‘disengaged’ patient. To do so, we highlight recent studies that evaluate 
telecommunication technologies in special or vulnerable populations of patients with 
diabetes. This includes pregnant women, Veterans, patients from rural or urban 
communities, and patients with poorly-controlled diabetes.  
Recent Findings 
 The following highlighted studies were published between 2014-2015. They are 
separated into two categories, studies aimed to evaluate acceptability, feasibility, and 
preliminary efficacy of a new technological innovation to a certain group of patients or 
practice and studies aimed to evaluate efficacy of such interventions.  
Evaluating Acceptability, Feasibility, and Preliminary Efficacy  
As new technologies are introduced to patients, it is important to evaluate 
acceptability by both patients and their care teams, feasibility of integrating into current 
care patterns and preliminary efficacy. Several studies published in the past year aimed to 
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evaluate acceptability of new technologies. Many of these studies are qualitative in 
nature, limited in the number of study participants, and last for a brief duration of time. 
While not intended to assess long-term clinical or patient-reported efficacy, these studies 
serve as a critical first step in evaluating the introduction of emerging technological 
interventions.  
Even for technologies that have previously shown to be beneficial, it is important 
to replicate results in different populations and settings. This is particularly true for 
disengaged patients for which the potential benefits of telecommunication technologies 
are great. Siminerio et al.[100] found that patients in rural populations receiving 
consultations with endocrinologists through a videoconferencing intervention reported 
high levels of satisfaction and improvements in patient empowerment, self-care skills, 
and reduction in diabetes distress. Robinson et al.[101] also evaluated the use of 
videoconferencing home consultations for patients with poorly controlled diabetes and 
found the majority of patients were satisfied with the technology. Care team members 
also reported satisfaction and noted advantages such as reaching patients who typically 
are absent from in-person visits, improved real-time treatment and management, and 
being able to view a patient’s home setting including their food items and prescription 
bottles. Given et al.[102] conducted a small randomized controlled trial (RCT) pilot of 
patients with gestational diabetes to evaluate an intervention consisting of weekly blood 
pressure, weight measurement, and SMBG recordings transmitted through a telemedicine 
hub by patients for review by a care team member. The majority of patients receiving the 
intervention reported being satisfied and both patients and providers reported that the 
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technology was easy to use. Providers also expressed that in the future if telemedicine 
replace regular appointments that protected time would be necessary.  Welch et al.[103] 
also looked at satisfaction of a 3-month telemedicine intervention primarily among 
African-American and Latino patients with poorly controlled diabetes at an urban 
community health center. The intervention consisted of a home monitoring device 
connected to an electronic pillbox, a Bluetooth®-enabled glucose meter and a blood 
pressure monitor with telehealth nurses receiving regular data alerts from the home 
monitoring system and calling patients at scheduled intervals. They found consistently 
high ratings of usability and program satisfaction from patients and providers. 
Additionally, they found clinically and statistically significant improvements in blood 
glucose control.  
Evaluating efficacy 
While evaluating the acceptability, feasibility, and preliminary efficacy of new 
technologies used to manage diabetes is a critical first step, the effects on clinical and 
patient-reported outcomes should also be assessed to establish efficacy. Several studies 
over the past year investigated the effects of using telehealth systems, videoconferencing, 
and mHealth interventions to improve the management of diabetes in difficult to manage 
or disengaged patient populations.  
Telehealth systems with remote monitoring devices 
 Carral et al.[104] examined the effects of a telehealth system that supported web-
based manual entry of SMBG values, insulin dose administration, and carbohydrates 
consumed followed by regular asynchronous communication with a care team compared 
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to usual care in a population of pregnant women. While they found no significant 
difference in mean A1c change during pregnancy or after delivery, patients in the 
telehealth group required insulin therapy less frequently and had significantly lower 
number of clinical visits. Since standard care for women with gestational diabetes calls 
for intensive glucose assessments every 1-2 weeks, the use of telehealth to reduce overall 
in-person visits while maintaining similar levels of glycemic control and maternal and 
neonatal outcomes may be particularly beneficial for those with difficulty frequently 
attending in-person visits.  
Shane-McWhorter et al.[41] conducted a case-control study to assess the effects 
of a remote monitoring system to provide electronic preprogrammed feedback 
supplemented by pharmacist Certified Diabetes Educators (CDEs) in a predominately 
Hispanic population recruited from community health centers. A1c was significantly 
lower in the telemonitoring group (2.07% decrease vs. 0.66% decrease). They also found 
a positive improvement in patient-reported outcomes such as self-efficacy and diabetes 
and hypertension knowledge in the intervention group.  
 Crowley et al.[72] evaluated the use of an interactive voice response (IVR) 
system in a veteran population with poorly controlled diabetes. Veterans randomized to 
the intervention group monitored their blood glucose levels before meals and at bedtime 
and received daily IVR calls to report their SMBG recordings followed by regular 2-
week calls from home telehealth nurses to review SMBG data, reconcile medications, 
assess medication adherence, and administer a diabetes self-management support module. 
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After 6 months, A1c had improved by 1.3% for intervention participants compare to 
0.3% for usual care participants. 
 Nicolucci et al.[62] evaluated the use of a home telehealth system for patients 
with poorly-controlled diabetes to monitor body weight, blood glucose, and blood 
pressure values with a Bluetooth®-connected hub with educational support provided by a 
general practitioner. In this RCT, the telehealth group saw significant reduction in A1c 
levels, improvement in patient-reported quality of life, and reduction of specialist visits 
compared with the control group.  
Videoconferencing consultations 
 Videoconferencing offers a potential solution for patients who are disengaged due 
to inability to regularly attend in-person visits. Young et al.[42] conducted an RCT to 
examine the effects of a nurse delivered telehealth coaching intervention for patients with 
diabetes living in rural communities. Intervention participants were offered nurse 
coaching via either telephone or videoconferencing. They found significantly higher self-
efficacy scores for patients receiving the intervention compared to those in the control 
group. Trends towards significance were also noted for improved physical health, mental 
health, and satisfaction with care. 
  Harris et al.[105] conducted an RCT to compare the effectiveness of delivering 
the Behavioral Family Systems Therapy for Diabetes (BFST-D) in clinic compared to 
videoconferencing in a population of patients with poorly controlled Type 1 diabetes.  
They found statistically significant improvements in adherence and glycemic control in 
both groups with no significant between-group differences.  
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mHealth Interventions 
 Interventions involving mHealth have potential to reach the increasingly number 
of patients with cell phones. Arora et al.[71] conducted an RCT to test the effects of a 6 
month text message program targeting low-income, Spanish speaking patients with 
poorly-controlled diabetes from an urban, public emergency room setting. Intervention 
participants received 2 daily text messages intended to enhance patient motivation, self-
efficacy, and ability to perform diabetes self-care behaviors. They also found trends of 
greater improvement in A1c change, medication adherence, and reduced utilization of 
emergency services. 
 Levy et al.[82] also evaluated a mHealth intervention in an urban, low-income 
population. They conducted an RCT to test the effects of using text messages and phone 
calls to help patients reach optimal insulin dose within 12 weeks. Patients randomized to 
the intervention group received weekday text messages requesting their fasting blood 
glucose values which were monitored by a nurse who would call the patient to adjust 
insulin doses. They found a significantly greater proportion of patients in the intervention 
group reached their optimal insulin dose than patients in the control group. Patients 
receiving the intervention also reported higher treatment satisfaction compared to the 
control group. 
Summary 
 Telecommunication technologies have shown promise of improving self-
management skills and medical care for patients who are likely to be disengaged with the 
management of their health. Moving forward, it will be important to target specific 
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populations of patients and provide appropriate technology, training, support, and 
motivation to utilize such technologies to achieve maximum benefits. The key to 
maintaining engagement in such interventions appears to be continual support and 
interaction between patients and their care teams. It is also important to implement 
targeted telecommunication technology interventions that demonstrate benefits in pilot 
and efficacy testing into everyday practice. Ideally, telecommunication technologies 
should be utilized in a fashion that not only helps patients improve self-management of 
their disease but also to help providers deliver more efficient, coordinated, and quality 
health care to patients with diabetes.  
Key Points 
• Recent studies have shown that telecommunication technologies can improve 
management of diabetes.  
• Highlighted studies evaluate the use of patient portals, videoconferencing, 
telehealth systems, and mHealth telecommunication technologies on the delivery 
of care and patient self-management of diabetes.  
• The use of telecommunication technologies has shown to be particularly 
beneficial in reaching disengaged, special, or vulnerable populations of patients 
with diabetes.  
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Table S.1. Characteristics and Results of Acceptability and Feasibility Studies involving the use of telecommunication technologies in 
Diabetes 
1st 
Author, 
year 
Study Aim Study 
Type 
N DM Type,  
 
Study 
Population 
Telecommunication 
Tools  
Main Findings 
Siminerio, 
2014 [100] 
To examine diabetes-related 
behavioral and psychosocial 
outcomes as well as patient 
satisfaction with the 
Telemedicine for Reach, 
Education, Access, and 
Treatment (TREAT) model. 
Prospective 
Cohort 
35 T2DM 
 
Rural 
Population 
Videoconferencing Patients reported high levels of satisfaction 
and significant improvement in 
empowerment, self-care, and reduction in 
diabetes distress 
Robinson, 
2015 [101] 
To determine satisfaction and 
usability of patients and 
diabetes care team members 
with videoconferencing 
capabilities.  
 
Prospective 
Cohort   
34 T2DM 
 
Poorly 
controlled 
diabetes 
population 
Videoconferencing  83%% of patients reported 
videoconferencing was as helpful as and 
more convenient than an office visit.  76% 
agreed that FaceTime was effective in 
improving diabetes.  
Given, 
2015 [102] 
To determine the feasibility and 
acceptability of using 
telemedicine in the diabetes 
care of women with GDM and 
the possibility of replacing 
alternate diabetes review 
appointments with 
telemedicine. 
RCT Pilot 50 GDM 
 
Pregnant 
women 
population 
Home monitoring Eighty-nine percent of patients were 
satisfied with telemedicine and would use it 
again. Both HCPs and patients found the 
equipment easy to use and were positive 
about using it to replace alternate diabetes 
review appointments in the future. 
Healthcare providers felt that protected 
time in which to perform the telemedicine 
review would be necessary. 
Welch, To examine the usability, 
satisfaction, and clinical impact 
Prospective 30 T2DM Home monitoring, 
Scheduled nurse 
High levels of remote home monitoring 
device use during the intervention period, 
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2015 [103] of a 3-month diabetes 
telehealth intervention for 
poorly controlled type 2 
diabetes (T2D) patients.  
 
Cohort  
Urban 
population 
coaching high ratings of usability and program 
satisfaction from patients, and high ratings 
of provider satisfaction with the program. 
Clinically and statistically significant 
improvement in blood glucose control at 3 
months.  
Table S.2. Characteristics and Results of Studies evaluating telecommunication technologies in Diabetes 
1st Author, 
year 
Study Aim Study 
Type 
N DM Type, 
Study 
population/ 
setting 
Telecommunication 
Tools Examined 
Main Findings 
Carral,  
2015 [104] 
To examine the impact of a Web-
based telemedicine system for 
monitoring glucose control in 
pregnant women with diabetes on 
healthcare visits, metabolic 
control, and pregnancy outcomes 
Prospective 
Cohort 
104 GDM, 
T1DM, 
T2DM 
Pregnant 
women 
population 
Telehealth system 
with manual data 
entry and 
asynchronous 
communication 
No significant differences in A1c level 
during pregnancy or after delivery, 
despite a significantly lower number of 
visits to the Gestational Diabetes Unit 
(3.2±2.3 vs. 5.9±2.3 visits; P<0.001), 
nurse educator (1.7±1.3 vs. 3.0±1.7 
visits; P<0.001), and general 
practitioner (3.7±2.0 vs. 4.9±2.8 visits; 
P<0.034) in the telemedicine group.  
Shane-
McWhorter,  
2015 [41] 
To assess clinical outcomes (A1c, 
blood pressure, and lipids) and 
other measurements (disease state 
knowledge, adherence, and self-
efficacy) associated with the use 
of telemonitoring devices to 
expand and improve chronic 
disease management of patients 
with diabetes, with or without 
Case-
Control 
150 T2DM 
 
Majority 
Spanish 
speaking,  
community 
health 
center 
Telehealth system 
with automatic or 
manual blood 
pressure and manual 
blood glucose and 
weight data entry,  
asynchronous 
communication, 
pharmacist coaching 
Change in A1cwas significantly greater 
in the telehealth group compared with 
the usual care group (2.07% decrease 
vs. 0.66% decrease; P <0.001). Patient 
activation measure, 
diabetes/hypertension knowledge, and 
medication adherence with 
antihypertensives (but not diabetes 
medications) improved in the telehealth 
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hypertension. population phone sessions group.  
Crowley, 
2015 [72] 
To evaluate a comprehensive 
telemedicine intervention 
specifically designed for delivery 
using existing Veterans Health 
Administration (VHA) clinical 
staffing and equipment. 
RCT  50 T2DM 
 
Veteran 
population  
Telehealth system 
with IVR reporting 
of home monitoring 
and scheduled nurse 
telephone contact 
By 6 months, estimated HbA1c had 
improved by 1.3% for intervention 
participants and 0.3% for usual care. 
Intervention participants' diabetes self-
care, systolic blood pressure, and 
diastolic blood pressure were improved 
versus usual care at 6 months 
Nicolucci,  
2015 [62] 
To evaluate whether a home 
telemedicine system enabling the 
patient to monitor body weight, 
blood glucose values, and blood 
pressure values, associated with 
remote educational support and 
feedback to the general 
practitioner, can improve 
metabolic control and overall 
cardiovascular risk in individuals 
with type 2 diabetes mellitus, 
compared with usual practice. 
RCT 302 T2DM 
 
Poorly 
controlled 
diabetes 
population 
Telehealth system, 
remote monitoring 
devices, nurse 
coaching phone 
sessions 
Use of the telehealth system was 
associated with a statistically significant 
reduction in A1c levels compared with 
the control group (estimated mean 
difference, 0.33±0.1; P=0.001. 
Significant differences in favor of the 
telehealth group were detected as for 
physical functioning (P=0.01), role 
limitations due to emotional problems 
(P=0.02), mental health (P=0.005), and 
mental component summary (P=0.03) 
scores. Lower number of specialist 
visits was reported in the telehealth 
group (incidence rate ratio, 0.72; 95% 
confidence interval, 0.51–1.01; P=0.06). 
Young,  
2014 [42] 
To evaluate the benefits of nurse 
telehealth coaching for persons 
with diabetes living in rural 
communities through a person-
centered approach using 
motivational interviewing (MI) 
RCT 101 T1DM, 
T2DM 
 
Rural 
community 
Videoconferencing 
with nurse coaching 
sessions 
Significantly higher self-efficacy scores 
in the intervention group compared with 
the control group based on the DES at 9 
months (4.03 versus 3.64, respectively; 
p<0.05).  
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techniques population  
Harris,  
2015 [105] 
To compare the relative 
effectiveness of two modes of 
delivering Behavioral Family 
Systems Therapy for Diabetes 
(BFST-D) to improve adherence 
and glycemic control among 
adolescents with type 1 diabetes 
with suboptimal glycemic 
control: face to face in clinic and 
Internet videoconferencing 
conditions. 
RCT 90 T1DM 
 
Poorly 
controlled 
diabetes 
population 
Videoconferencing No between-group differences in 
treatment effects for adherence and 
glycemic control ( P = 0.77) 
Arora,  
2014 [71] 
To determine whether a scalable, 
low-cost, unidirectional, text 
message–based mobile health 
intervention (TExT-MED) 
improves clinical outcomes, 
increases healthy behaviors, and 
decreases ED utilization in a 
safety net population. 
RCT 128 T2DM 
 
Emergency 
department 
setting, 
low-income 
population 
mHealth 
intervention with 
text messaging 
A1c level decreased by 1.05% in the 
TExT-MED group compared with 
0.60% in the controls (Δ0.45; 95% 
confidence interval [CI] -0.27 to 1.17) 
at 6 months. Self-reported medication 
adherence (Morisky Medication 
Adherence Scale) improved from 4.5 to 
5.4 in the TExT-MED group compared 
with a net decrease of -0.1 in the 
controls (Δ1.1 [95% CI 0.1 to 2.1]). 
Effects were larger among Spanish 
speakers for both medication adherence 
(1.1 versus -0.3; Δ1.4; 95% CI 0.2 to 
2.7) and A1c (-1.2% versus -0.4%) in 
the TExT-MED group. The proportion 
of patients who used emergency 
services trended lower in the TExT-
MED group (35.9% versus 51.6%; 
Δ15.7%; 95% CI 9.4% to 22%). 93.6% 
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of respondents enjoyed TExT-MED and 
100% would recommend to 
family/friends. 
Levy,  
2015 [82] 
To evaluate if Mobile Insulin 
Titration Intervention (MITI) 
intervention using text messaging 
and phone calls was effective in 
helping patients reach their 
optimal insulin glargine dose 
within 12 weeks, assess the 
feasibility of the intervention 
within our clinic setting and 
patient population, collect data on 
the cost savings associated with 
the intervention, and measure 
patient satisfaction with the 
intervention.  
RCT 61 T2DM 
 
Urban, low-
income 
population 
mHealth 
intervention with 
text messaging and 
weekly phone 
sessions 
A significantly greater proportion of 
patients in the intervention arm reached 
their optimal insulin glargine dose than 
patients in the usual care arm. Patients 
responded to 84.3% of the SMS text 
messages requesting their blood glucose 
values. The nurse reached patients 
within 2 attempts or by voicemail 91% 
of the time. The intervention was cost 
saving in terms of time for patients, 
who were able to have their insulin 
titrated without multiple clinic 
appointments. After participating in the 
study, patients in the intervention arm 
reported higher treatment satisfaction 
than those in the usual care arm. 
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